ClinicalTrials.gg
CompletedNCT03961009CARES10Updated May 5, 2026Results posted

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients

A Phase 3 interventional study of Kedrion IVIG 10% in Primary Immunodeficiency Disease, sponsored by Kedrion S.p.A.. Completed at 11 sites in United States. Open to participants aged 2 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Kedrion S.p.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
2 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases — 2 open to participants now, 4 under way, 4 of them phase 3. Immunoglobulins, Intravenous · Primary Immunodeficiency Diseases.

Enrollment
12th of 26
47 · median 45
Started
2019
the only one that year
Phase 3
18 of 27
2 open now
Registered
22nd of 27
by date
Lead sponsor
3 of 27
Kedrion S.p.A.

Among the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, this one is the 12th largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2019, is one of 18 in phase 3, and was the 22nd registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

2 of the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases are open now. Recruiting first, the newest first:

All 2 open studies →

About Immunoglobulins, Intravenous

Immunoglobulins, Intravenous: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, or all of them as a file.
02

Study summary

The purpose of this study was to assess efficacy and safety of Kedrion Immunoglobulin 10% (KIg10) in participants with Primary Immunodeficiency (PID).

03

Conditions studied

  • Primary Immunodeficiency Disease

Keywords

  • Immunoglobulin
  • Kedrion IVIg10%
  • IgG antibodies
  • Agammaglobulinemia
  • Hypogammaglobulinemia
04

Who can participate

Ages eligible
2 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written /assent obtained from participant/participant's parent(s) or legally acceptable representative indicating that they understand the purpose of and procedures required for the study and are willing to participate in it.
  • Confirmed clinical diagnosis of a PID, requiring treatment with IVIg and have documented agammaglobulinemia (defined as the total absence of one or more classes of antibodies) or hypogammaglobulinemia (defined as low levels of one or more classes [that is at least 2 standard deviations under the mean level per age])
  • Male or female, ages 2 to 70 years at screening
  • Received 200 to 800 mg/kg of a commercially available IVIg therapy in the range of 21- or 28-day intervals (±3 days or ±4 days, respectively) for at least 3 infusion cycles prior to screening
  • At least 2 documented IgG trough levels while receiving an IVIg, of greater than or equals to (>=) 6 gram per liter (g/L) obtained at 2 infusion cycles within 12 months (1 must be within 6 months) prior to Informed Consent Form (ICF) signature
  • Participant is willing to comply all requirements of the protocol.
  • Females of with a negative urine pregnancy test and who agree to employ adequate measures during the study
  • Authorization to access personal health information
  • Participant previously participating in a clinical trial with another experimental IVIg may be enrolled if they have received stable commercially available IVIg therapy for at least 3 infusion cycles (21 or 28 days) prior to screening
  • Participant currently on treatment with any subcutaneous immunoglobulin (SCIG) can be enrolled if they are switched to stable commercially available IVIg therapy for at least 3 infusion cycles (21 or 28 days) prior to screening

Exclusion criteria

Exclusion Criteria:

  • Newly diagnosed PID and and naïve to IgG replacement therapy
  • Dysgammaglobulinemia (defined as a deficiency in one or more classes of antibodies, but not severe enough to require substitutive therapy) or isolated IgG subclass deficiency or profound primary T-cell deficiency (defined as the absence or severe reduction of T lymphocytes [CD3+ \<300 cells per cubic millimeter (cell/mm3)] and an absent or particularly low proliferative response [10% of the lower normal range] to phytohaemagglutinin P [PHA])
  • Has history of severe or serious reactions or to IVIg or other injectable forms of IgG
  • Has history of thrombotic events (including deep vein thrombosis, cerebrovascular accident, pulmonary embolism, , or myocardial infarction), as defined by at least 1 event in participant's lifetime
  • Has IgA deficiency with documented antibodies to IgA
  • Have received blood products that have not undergone viral inactivation measures within 12 months prior to Form (ICF) signature
  • Has significant protein losing enteropathy, nephrotic syndrome, or lymphangiectasia
  • Has an acute infection as documented by culture or diagnostic imaging and/or a body temperature >= 38 degree Celsius (°C) (>=100.4 degree Fahrenheit (°F) within 7 days prior to screening
  • Has acquired immunodeficiency syndrome (AIDS) and/or /C active disease at ICF signature
  • Has levels of (ALT) or aspartate aminotransferase (AST), 2.5 times of the for the laboratory designated for the study
  • Using an implanted venous access device
  • Has profound anemia ( less than10 gram per deciliter [g/dl]) or persistent severe neutropenia (\<= 1000 neutrophils per millimeter cube (mm\^3) or lymphopenia of less than 500 cells per microliter
  • Have severe chronic condition such as renal failure (creatinine concentration > 2.0 times the upper limit of normal) with proteinuria, congestive heart failure ( III/IV), cardiomyopathy, cardiac arrhythmia associated with thromboembolic events (e.g., atrial fibrillation), unstable or advanced ischemic heart disease, hyper viscosity, or any other condition that the Investigator believes is likely to interfere with evaluation of the study drug or with satisfactory conduct of the trial. Normal values for serum creatinine are the following: a) Female (18+ years): 45 - 84 micromole per liter (mcmol/L) or 0.51 - 0.95 milligrams per deciliter (mg/dl); b) Male (18+ years): 59 - 103 mcmol/L or 0.67 - 1.17 mg/dl
  • Has history of a malignant disease other than properly treated carcinoma in situ of the cervix or basal cell or squamous cell carcinoma of the skin within 24 months prior to ICF signature
  • Has history of pharmacoresistant epilepsy or multiple episodes of migraine (defined as at least 1 episode within 6 months of ICF signature) not completely controlled by medication
  • Participants must not be receiving (oral or parenteral daily dose of >= 0.15 milligram per kilogram per day (mg/kg/day) of prednisone or equivalent) or other drugs or chemotherapy
  • Females who are pregnant, breast feeding or planning a pregnancy during the course of the study. Women who become pregnant during the study will be withdrawn from the study
  • Has participated in another clinical study within 3 weeks prior to study ICF signature
  • Has history of drug or alcohol abuse within the 6 months before screening
  • Has Employed or a direct relative of an employee of the CRO, the study site, or the Sponsor
  • Previously treated under this protocol
  • Unable to provide informed consent or provide informed consent by a legally authorized representative
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Kedrion IVIG 10%

    Participants received intravenous infusion of Kedrion IVIG 10% at a dose of 200 to 800 milligrams per kilogram (mg/kg) body weight on every 21 or 28 days for period of 48 weeks.

    Biological: Kedrion IVIG 10%

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence Rate of Acute Serious Bacterial Infections (ABSIs)

    Incidence rate was defined as the mean number of acute serious bacterial infections (bacterial pneumonia, bacteremia/sepsis, bacterial meningitis, visceral abscess, osteomyelitis/septic arthritis) per participant-year according to pre-specified criteria.

    Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)

Secondary outcomes

  1. Serum Immunoglobulin G (IgG) Trough Levels

    The serum IgG trough levels were collected and analyzed at a central laboratory.

    Time frame: At baseline, Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)

  2. Immunoglobulin G (IgG) Subclasses Levels (IgG1, IgG2, IgG3, IgG4)

    IgG subclasses levels (IgG1, IgG2, IgG3, IgG4) were collected and analyzed at a central laboratory.

    Time frame: At baseline, Weeks 16, 32 and 48 (28-day dosing schedule); Weeks 18, 30, 48 (21-day dosing schedule)

  3. Number of Participants With Total Immunoglobulin G (IgG) Trough Levels Less Than or Equal to (<=) 6 Grams/Liter (g/L) Criteria

    Number of participants with Total IgG trough levels \<= 6 g/L criteria were reported.

    Time frame: Up to 12 months

  4. Anti-Tetanus Toxoid Antibody Levels

    The anti-tetanus toxoid antibody levels were collected and analyzed at a central laboratory. This antibody level was measured in international units per milliliter (IU/mL).

    Time frame: Baseline, Weeks 16, 32 and 48 (28-day dosing schedule); Weeks 18, 30, 48 (21-day dosing schedule)

  5. Anti-Pneumococcal Capsular Polysaccharide Antibody Levels

    Anti-pneumococcal capsular polysaccharide antibody levels for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 were collected and analyzed at a central laboratory.

    Time frame: Baseline, Weeks 16, 32 and 48 (28-day dosing schedule); Weeks 18, 30, 48 (21-day dosing schedule)

  6. Anti-Measles Antibody Levels

    The anti-measles antibody levels were collected and analyzed at a central laboratory.

    Time frame: Baseline, Weeks 16, 32 and 48 (28-day dosing schedule); Weeks 18, 30, 48 (21-day dosing schedule)

  7. Anti-Haemophilus Influenza Type B Antibody Levels

    The anti-haemophilus influenza type B antibody levels were collected and analyzed at central laboratory.

    Time frame: Baseline, Weeks 16, 32 and 48 (28 -day dosing schedule); Weeks 18, 30, 48 (21-day dosing schedule)

  8. Incidence Rate of Any Infection Other Than Acute Serious Bacterial Infections

    Incidence rate was defined as the mean number of any infection other than acute serious bacterial infections (bacterial pneumonia, bacteraemia/sepsis, bacterial meningitis, visceral abscess, osteomyelitis/septic arthritis) per participant-year. Incidence rate of any infection other than acute bacterial serious infections collected by the participant/participants parent(s)/legal guardian(s) in the participant diary or during clinic visit was reported.

    Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)

  9. Duration of Any Infection Other Than Acute Serious Bacterial Infections

    Duration of any infection other than serious acute bacterial infections (in days) was calculated as date of stop of infection - date of start of infection + 1. Duration of any infection other than serious acute bacterial infections collected by the by the participant/participants parent(s)/legal guardian(s) in the participant diary or during clinic visit was reported.

    Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)

  10. Incidence Rate of Fever Episodes

    Incidence rate was defined as the mean number of fever episodes per participant-year. Incidence rate of fever episodes collected by the participant/participant's parent(s)/legal guardian(s) in the participant diary or during clinic visit were reported.

    Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)

  11. Duration of Fever Episodes in Participants

    Duration of fever episodes in participants was reported.

    Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)

  12. Duration of Overall Participants Hospitalization

    Duration of overall participants hospitalization was reported.

    Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)

  13. Duration of Participants Hospitalization Due to Infection

    Duration of participants hospitalization due to infection was reported.

    Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)

  14. Incidence Rate of Antibiotics Episodes for Treatment of Any Kind of Infections

    Incidence rate was defined as the mean number of antibiotics episodes per participant year. Incidence rate of participants on antibiotics for treatment of any kind of infections was reported.

    Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)

  15. Duration of Participants on Antibiotics for Treatment of Any Kind of Infection

    Duration of participants on antibiotics for treatment of any kind of infection was reported.

    Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)

  16. Duration of Missed School/Work/Other Major Activities Due to Infections

    Duration of missed school/work/other major activities due to infections was reported.

    Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)

  17. Pediatric Quality of Life Inventory (PedsQL) Score

    23-item PedsQL generic core scales was a modular approach to measure health-related Quality of Life (QoL) in healthy children, adolescents and those with acute and chronic health conditions. The total scale score (23 items) consisted of Physical Health Summary Score (8 items) and Psychosocial Health SummaryScore (15 items). Physical health summary included Physical Functioning (8 items) and Psychosocial health summary score included Emotional Functioning (5 items), Social Functioning (5 items) and School Functioning (5 items). Items were scored on a 5 point Likert-type response scale: 0=never a problem; 1=almost never a problem; 2=sometimes a problem; 3=often a problem; and 4=almost always a problem). Once scored, items were reverse scored and linearly transformed to a 0-100 scale, where higher scores indicated better QoL. The overall range for total PedsQL score (23 items) was 0 to 100, with higher score indicated better QoL. Data for 18-25 years and \>25 years age group was reported.

    Time frame: Baseline, Week 24 (21-day dosing schedule and 28-day dosing schedule), Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)

  18. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

    An adverse event (AE) was defined as any untoward medical occurrence in a participant administered a study drug which may or may not have a causal relationship with the study drug. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life- threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAE was defined as an AE with an onset that occurs after receiving study drug. Any TEAE included participants with both serious and non-serious TEAEs.

    Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)

  19. Number of TEAEs and Serious TEAEs

    An adverse event (AE) was defined as any untoward medical occurrence in a participant administered a study drug which may or may not have a causal relationship with the study drug. A SAE was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life- threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. A TEAE was defined as an AE with an onset that occurs after receiving study drug. Number of TEAEs and Serious TEAEs were reported.

    Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)

  20. Number of Drug Related Infusion Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a participant administered a study drug which may or may not have a causal relationship with the study drug. Number of drug related infusion AEs were reported.

    Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)

  21. Percentage of Participants Who Experienced at Least One Drug Related Infusion Adverse Events (AEs)

    Percentage of participants who experienced at least one drug related infusion AEs were reported.

    Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)

  22. Number of Infusions With Decreased Infusion Rate Due to Adverse Events (AEs)

    Number of infusions with decreased infusion rate due to AEs were reported.

    Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)

  23. Number of Infusions With One or More Infusion Associated Adverse Events (AEs)

    The number of infusions with one or more infusion associated AEs were reported collectively for 21 and 28-day dosing schedule up to Week 52.

    Time frame: Baseline up to Week 52

  24. Number of Participants With Clinically Significant Changes From Baseline in Vital Signs

    Vital signs included body temperature, systolic and diastolic blood pressure, heart rate and weight. The systolic and diastolic blood pressure and pulse rate was measured after the participants have in a rested at least 3 minutes in seated position. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in vital signs were reported.

    Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)

  25. Number of Participants With Clinically Significant Changes From Baseline in Physical Examinations

    Physical examination included the examination of general appearance, skin, neck, eyes, ears, nose, throat, cardiovascular assessment including rhythm, and presence of other cardiac abnormalities (for example gallops, murmurs, cardiomegaly), respiratory system, gastrointestinal system, genitourinary system and musculoskeletal system. Clinical significance was decided by the investigator. The number of participants with clinically significant changes from baseline in physical examination were reported.

    Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)

  26. Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameters

    Laboratory parameters included chemistry, hematology and urinalysis. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in laboratory parameters were reported.

    Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)

  27. Number of Participants With Positive Coomb's Test at Week 16 (28-day Dosing Schedule) and Week 18 (21-day Dosing Schedule)

    Intravascular hemolysis testing was performed by using coomb's test. The coomb's assessment was performed at a central laboratory.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule)

  28. Number of Participants With Positive Urine Hemosiderin Test

    Number of participants with positive urine hemosiderin test were reported.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule)

  29. Number of Participants With Abnormal Plasma-free Haemoglobin Level

    Number of participants with plasma-free haemoglobin level more than or equal to (\>=) 69 milligrams per deciliter (mg/dL) were consisdered as abormal and were reported.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule)

  30. Number of Participants With Abnormal Serum Haptoglobin Level

    Number of participants with abnormal serum haptoglobin level were reported.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule)

  31. Maximum Observed Serum Concentration (Cmax) of Total Immunoglobulin G (IgG)

    Cmax was obtained directly from the concentration versus time curve. Both baseline corrected and un-corrected data was reported.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  32. Elimination Half-Life (t1/2) of Total IgG

    t1/2 was the time measured for the concentration to decrease by one half. t1/2 was calculated by natural log 2 divided by Kel. Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase. Both baseline corrected and un-corrected data was reported.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  33. Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of Total IgG

    Area under the serum concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLOQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule. Both baseline corrected and un-corrected data was reported.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  34. Area Under the Serum Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Total IgG

    AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Kel, where Clast pred was the calculated serum concentration at the last sampling time point at which the measured serum concentration is at or above the Lower Limit of quantification (LLOQ) and Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase. Both baseline corrected and un-corrected data was reported.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  35. Area Under the Serum Concentration-Time Curve During a Dosing Interval (AUCtau) of Total IgG

    AUCtau was defined as area under the serum concentration-time curve from time zero to the end of the dosing interval (tau). AUCtau was calculated using the mixed log linear trapezoidal rule. Both baseline corrected and un-corrected data was reported.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  36. Volume of Distribution (Vd) of Total IgG

    Vd was defined as the the theoretical volume in which the total amount of total IgG would need to be uniformly distributed to produce the desired blood concentration of a total IgG. Both baseline corrected and un-corrected data was reported.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  37. Steady State Clearance (CLss) of Total IgG

    Clearance of a total IgG was a measure of the rate at which a total IgG is metabolized or eliminated by normal biological processes. CLss of total IgG was measured in milliliters per hour per kilogram (mL/hr/kg). Both baseline corrected and un-corrected data was reported.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  38. Minimum Observed Serum Concentration (Cmin) of Total IgG

    Cmin was minimum observed serum concentration obtained directly from the concentration versus time curve. Both baseline corrected and un-corrected data was reported.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  39. Time to Reach the Maximum Serum Concentration (Tmax) of Total IgG

    Tmax was obtained directly from the concentration versus time curve. Both baseline corrected and un-corrected data was reported.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  40. Elimination Rate Constant (Kel) of Total IgG

    Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase. Both baseline corrected and un-corrected data was reported.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  41. Average Concentration of Total IgG Over the Dosing Interval (Cavg)

    Average concentration of total IgG over the dosing interval (Cavg) was reported. Both baseline corrected and un-corrected data was reported.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  42. Percentage Peak Trough Fluctuation of Total IgG

    The peak trough fluctuation within complete dosing interval at steady state of total IgG was reported. Both baseline corrected and un-corrected data was reported.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  43. Maximum Observed Serum Concentration (Cmax) of Antigen-Specific Tetanus Toxoid Antibodies

    Cmax was obtained directly from the concentration versus time curve.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  44. Elimination Half-Life (t1/2) of Antigen-Specific Tetanus Toxoid Antibodies

    t1/2 was the time measured for the concentration to decrease by one half. t1/2 was calculated by natural log 2 divided by Kel. Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  45. Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of Antigen-Specific Tetanus Toxoid Antibodies

    Area under the serum concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLOQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule. The AUC0-t of antigen-specific tetanus toxoid antibodies was measured in hour\*international units per milliliter (hr\*IU/mL).

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  46. Area Under the Serum Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Antigen-Specific Tetanus Toxoid Antibodies

    AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Kel, where Clast pred was the calculated serum concentration at the last sampling time point at which the measured serum concentration is at or above the Lower Limit of quantification (LLOQ) and Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  47. Area Under the Serum Concentration-Time Curve During a Dosing Interval (AUCtau) of Antigen-Specific Tetanus Toxoid Antibodies

    AUCtau was defined as area under the serum concentration-time curve from time zero to the end of the dosing interval (tau). AUCtau was calculated using the mixed log linear trapezoidal rule.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  48. Volume of Distribution (Vd) of Antigen-Specific Tetanus Toxoid Antibodies

    Vd was defined as the the theoretical volume in which the total amount of antigen-specific tetanus toxoid antibodies would need to be uniformly distributed to produce the desired blood concentration of antigen-specific tetanus toxoid antibodies. The Vd of antigen-specific tetanus toxoid antibodies was measured in milligrams\*milliliter per international unit\*kilogram (mg\*mL/IU\*kg).

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  49. Steady State Clearance (CLss) of Antigen-Specific Tetanus Toxoid Antibodies

    Clearance of a antigen-specific tetanus toxoid antibodies was a measure of the rate at which a antigen-specific tetanus toxoid antibodies are metabolized or eliminated by normal biological processes. The CLss of antigen-specific tetanus toxoid antibodies was reported. The CLss of antigen-specific tetanus toxoid antibodies was measured in milligrams\*milliliter per hour\*international unit\*kilogram (mg\*mL/hr\*IU\*kg).

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  50. Minimum Observed Serum Concentration (Cmin) of Antigen-Specific Tetanus Toxoid Antibodies

    Cmin was minimum observed serum concentration obtained directly from the concentration versus time curve.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  51. Time to Reach the Maximum Serum Concentration (Tmax) of Antigen-Specific Tetanus Toxoid Antibodies

    Tmax was obtained directly from the concentration versus time curve.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  52. Elimination Rate Constant (Kel) of Antigen-Specific Tetanus Toxoid Antibodies

    Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  53. Average Concentration of Antigen-Specific Tetanus Toxoid Antibodies Over the Dosing Interval (Cavg)

    Average concentration of antigen-specific tetanus toxoid antibodies over the dosing interval (Cavg) was reported.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  54. Percentage Peak Trough Fluctuation of Antigen-Specific Tetanus Toxoid Antibodies

    The peak trough fluctuation within complete dosing interval at steady state of antigen-specific tetanus toxoid antibodies was reported.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  55. Maximum Observed Serum Concentration (Cmax) of Antigen-Specific Haemophilus Influenza Type B Antibodies

    Cmax was obtained directly from the concentration versus time curve.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  56. Elimination Half-Life (t1/2) of Antigen-Specific Haemophilus Influenza Type B Antibodies

    t1/2 was the time measured for the concentration to decrease by one half. t1/2 was calculated by natural log 2 divided by Kel. Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  57. Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of Antigen-Specific Haemophilus Influenza Type B Antibodies

    Area under the serum concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLOQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule. AUC0-t of antigen-specific haemophilus influenza Type B Antibodies was measured in hour\*microgram per milliliter (hr\*mcg/mL).

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  58. Area Under the Serum Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Antigen-Specific Haemophilus Influenza Type B Antibodies

    AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Kel, where Clast pred was the calculated serum concentration at the last sampling time point at which the measured serum concentration is at or above the Lower Limit of quantification (LLOQ) and Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  59. Area Under the Serum Concentration-Time Curve During a Dosing Interval (AUCtau) of Antigen-Specific Haemophilus Influenza Type B Antibodies

    AUCtau was defined as area under the serum concentration-time curve from time zero to the end of the dosing interval (tau). AUCtau was calculated using the mixed log linear trapezoidal rule.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  60. Volume of Distribution (Vd) of Antigen-Specific Haemophilus Influenza Type B Antibodies

    Vd was defined as the the theoretical volume in which the total amount of antigen-specific haemophilus influenza type B antibodies would need to be uniformly distributed to produce the desired blood concentration of a antigen-specific haemophilus influenza type B antibodies.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  61. Steady State Clearance (CLss) of Antigen-Specific Haemophilus Influenza Type B Antibodies

    Clearance of antigen-specific haemophilus influenza type B antibodies was a measure of the rate at which antigen-specific haemophilus influenza type B antibodies were metabolized or eliminated by normal biological processes. CLss of antigen-specific haemophilus influenza type B antibodies was measured in milliliter per hour per kilogram (mL/hr/kg).

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  62. Minimum Observed Serum Concentration (Cmin) of Antigen-Specific Haemophilus Influenza Type B Antibodies

    Cmin was minimum observed serum concentration obtained directly from the concentration versus time curve.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  63. Time to Reach the Maximum Serum Concentration (Tmax) of Antigen-Specific Haemophilus Influenza Type B Antibodies

    Tmax was obtained directly from the concentration versus time curve.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  64. Terminal Elimination Rate Constant (Lambda z) of Antigen-Specific Haemophilus Influenza Type B Antibodies

    Terminal Elimination Rate Constant (lambda z) derived if data allowed based on PK acceptance criteria

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  65. Average Concentration of Antigen-Specific Haemophilus Influenza Type B Antibodies Over the Dosing Interval (Cavg)

    Average concentration of antigen-specific haemophilus influenza type B antibodies over the dosing interval (Cavg) was reported.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  66. Percentage Peak Trough Fluctuation of Antigen-Specific Haemophilus Influenza Type B Antibodies

    The peak trough fluctuation within complete dosing interval at steady state of antigen-specific haemophilus influenza type B antibodies was reported.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  67. Maximum Observed Serum Concentration (Cmax) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)

    Cmax was obtained directly from the concentration versus time curve. The Cmax for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8, serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  68. Elimination Half-Life (t1/2) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)

    t1/2 was the time measured for the concentration to decrease by one half. t1/2 was calculated by natural log 2 divided by Kel. Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase.Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase. The t1/2 for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  69. Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)

    Area under the serum concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLOQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule. AUC0-t of antigen-pneumococcal capsular polysaccharide was measured in hour\*microgram per milliliter (hr\*mcg/mL). The AUC0-t for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  70. Area Under the Serum Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)

    AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Kel, where Clast pred was the calculated serum concentration at the last sampling time point at which the measured serum concentration is at or above the Lower Limit of quantification (LLOQ) and Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase. The AUC0-inf for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20 serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  71. Area Under the Serum Concentration-Time Curve During a Dosing Interval (AUCtau) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)

    AUCtau was defined as area under the serum concentration-time curve from time zero to the end of the dosing interval (tau). AUCtau was calculated using the mixed log linear trapezoidal rule. The AUCtau for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  72. Volume of Distribution (Vd) of of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)

    Vd was defined as the the theoretical volume in which the total amount of anti-pneumococcal capsular polysaccharide would need to be uniformly distributed to produce the desired blood concentration of a anti-pneumococcal capsular polysaccharide. The Vd for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  73. Steady State Clearance (CLss) of Anti-pneumococcal Capsular Polysaccharide Antibodies (Overall SP Serotypes)

    Clearance of a anti-pneumococcal capsular polysaccharide antibodies was a measure of the rate at which a anti-pneumococcal capsular polysaccharide antibodies are metabolized or eliminated by normal biological processes. The CLss of anti-pneumococcal capsular polysaccharide antibodies was reported. The CLss of anti-pneumococcal capsular polysaccharide antibodies was measured in milligrams\*milliliter per hour\*international unit\*kilogram (mg\*mL/hr\*IU\*kg). The CLss for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  74. Minimum Observed Serum Concentration (Cmin) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)

    Cmin was minimum observed serum concentration obtained directly from the concentration versus time curve. The Cmin for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  75. Time to Reach the Maximum Serum Concentration (Tmax) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)

    Tmax was obtained directly from the concentration versus time curve. The Tmax for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  76. Elimination Rate Constant (Kel) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)

    Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase. The Kel for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20 serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  77. Average Concentration of Anti-pneumococcal Capsular Polysaccharide the Dosing Interval (Cavg) (Overall SP Serotypes)

    Average concentration of anti-pneumococcal capsular polysaccharide over the dosing interval (Cavg) was reported. The Cavg for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

  78. Percentage Peak Trough Fluctuation of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)

    The peak trough fluctuation within complete dosing interval at steady state of anti-pneumococcal capsular polysaccharide was reported. The peak trough fluctuation for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.

    Time frame: At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion

07

Results

Posted Jan 27, 2022

Participant flow

This study was conducted at 11 sites in the United States from 30 April 2019 (first participant first visit) to 21 December 2020 (last participant last visit).

Participant flow — Overall Study
MilestoneKedrion IVIG 10%
Started47
Completed47
Not completed0

Outcome measures

PrimaryIncidence Rate of Acute Serious Bacterial Infections (ABSIs)

Incidence rate was defined as the mean number of acute serious bacterial infections (bacterial pneumonia, bacteremia/sepsis, bacterial meningitis, visceral abscess, osteomyelitis/septic arthritis) per participant-year according to pre-specified criteria.

Time frame:
Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Reported as:
Mean · infections per participant-year
Incidence Rate of Acute Serious Bacterial Infections (ABSIs)
infections per participant-yearKedrion IVIG 10%
21-day dosing schedule0.0 ± 0.0
28-day dosing schedule0.0 ± 0.0
SecondarySerum Immunoglobulin G (IgG) Trough Levels

The serum IgG trough levels were collected and analyzed at a central laboratory.

Time frame:
At baseline, Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Reported as:
Mean · grams per liter (g/L)
Serum Immunoglobulin G (IgG) Trough Levels
grams per liter (g/L)Kedrion IVIG 10%
Baseline10.317 ± 3.1342
21-day dosing schedule: Week 5111.433 ± 1.7935
28-day dosing schedule: Week 5210.297 ± 2.1167
SecondaryImmunoglobulin G (IgG) Subclasses Levels (IgG1, IgG2, IgG3, IgG4)

IgG subclasses levels (IgG1, IgG2, IgG3, IgG4) were collected and analyzed at a central laboratory.

Time frame:
At baseline, Weeks 16, 32 and 48 (28-day dosing schedule); Weeks 18, 30, 48 (21-day dosing schedule)
Reported as:
Mean · g/L
Immunoglobulin G (IgG) Subclasses Levels (IgG1, IgG2, IgG3, IgG4)
g/LKedrion IVIG 10%
IgG1: Baseline5.798 ± 1.7504
IgG1: 28-day dosing schedule: Week 165.605 ± 1.6115
IgG1: 21-day dosing schedule: Week 185.968 ± 1.5094
IgG1: 28-day dosing schedule: Week 325.679 ± 1.3965
IgG1: 21-day dosing schedule: Week 305.979 ± 0.9430
IgG1: 28-day dosing schedule: Week 485.634 ± 1.4139
IgG1: 21-day dosing schedule: Week 486.210 ± 0.9430
IgG2: Baseline3.527 ± 0.9635
IgG2: 28-day dosing schedule: Week 163.419 ± 0.8803
IgG2: 21-day dosing schedule: Week 184.113 ± 1.0155
IgG2: 28-day dosing schedule: Week 323.458 ± 0.7705
IgG2: 21-day dosing schedule: Week 304.079 ± 0.4975
IgG2: 28-day dosing schedule: Week 483.475 ± 0.7848
IgG2: 21-day dosing schedule: Week 484.234 ± 0.5649
IgG3: Baseline0.405 ± 0.3109
IgG3: 28-day dosing schedule: Week 160.351 ± 0.3459
IgG3: 21-day dosing schedule: Week 180.271 ± 0.1239
IgG3: 28-day dosing schedule: Week 320.352 ± 0.3461
IgG3: 21-day dosing schedule: Week 300.249 ± 0.0885
IgG3: 28-day dosing schedule: Week 480.329 ± 0.3268
IgG3: 21-day dosing schedule: Week 480.253 ± 0.0658
IgG4: Baseline0.2213 ± 0.12779
IgG4: 28-day dosing schedule: Week 160.2388 ± 0.09656
IgG4: 21-day dosing schedule: Week 180.2744 ± 0.06415
IgG4: 28-day dosing schedule: Week 320.2425 ± 0.09290
IgG4: 21-day dosing schedule: Week 300.2838 ± 0.06412
IgG4: 28-day dosing schedule: Week 480.2396 ± 0.09355
IgG4: 21-day dosing schedule: Week 480.2950 ± 0.05381
SecondaryNumber of Participants With Total Immunoglobulin G (IgG) Trough Levels Less Than or Equal to (<=) 6 Grams/Liter (g/L) Criteria

Number of participants with Total IgG trough levels \<= 6 g/L criteria were reported.

Time frame:
Up to 12 months
Reported as:
Count of participants · Participants
Number of Participants With Total Immunoglobulin G (IgG) Trough Levels Less Than or Equal to (<=) 6 Grams/Liter (g/L) Criteria
ParticipantsKedrion IVIG 10%
Number of Participants With Total Immunoglobulin G (IgG) Trough Levels Less Than or Equal to (<=) 6 Grams/Liter (g/L) Criteria1
SecondaryAnti-Tetanus Toxoid Antibody Levels

The anti-tetanus toxoid antibody levels were collected and analyzed at a central laboratory. This antibody level was measured in international units per milliliter (IU/mL).

Time frame:
Baseline, Weeks 16, 32 and 48 (28-day dosing schedule); Weeks 18, 30, 48 (21-day dosing schedule)
Reported as:
Mean · IU/mL
Anti-Tetanus Toxoid Antibody Levels
IU/mLKedrion IVIG 10%
Baseline2.526 ± 1.4158
28-day dosing schedule: Week 162.589 ± 2.0770
21-day dosing schedule: Week 182.654 ± 0.9853
28-day dosing schedule: Week 322.345 ± 0.8820
21-day dosing schedule: Week 302.643 ± 0.9374
28-day dosing schedule: Week 482.207 ± 0.8565
21-day dosing schedule: Week 483.299 ± 1.3307
SecondaryAnti-Pneumococcal Capsular Polysaccharide Antibody Levels

Anti-pneumococcal capsular polysaccharide antibody levels for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 were collected and analyzed at a central laboratory.

Time frame:
Baseline, Weeks 16, 32 and 48 (28-day dosing schedule); Weeks 18, 30, 48 (21-day dosing schedule)
Reported as:
Mean · milligrams per liter (mg/L)
Anti-Pneumococcal Capsular Polysaccharide Antibody Levels
milligrams per liter (mg/L)Kedrion IVIG 10%
Baseline: Serotype 12.66 ± 4.820
28-day dosing schedule: Week 16: Serotype 11.55 ± 1.481
21-day dosing schedule: Week 18: Serotype 14.89 ± 5.740
28-day dosing schedule: Week 32: Serotype 11.66 ± 2.114
21-day dosing schedule: Week 30: Serotype 14.74 ± 5.692
28-day dosing schedule: Week 48: Serotype 11.49 ± 1.707
21-day dosing schedule: Week 48: Serotype 14.28 ± 4.926
Baseline: Serotype 120.81 ± 1.103
28-day dosing schedule: Week 16: Serotype 120.75 ± 1.201
21-day dosing schedule: Week 18: Serotype 120.58 ± 0.175
28-day dosing schedule: Week 32: Serotype 120.86 ± 1.280
21-day dosing schedule: Week 30: Serotype 120.55 ± 0.120
28-day dosing schedule: Week 48: Serotype 120.82 ± 1.159
21-day dosing schedule: Week 48: Serotype 120.59 ± 0.090
Baseline: Serotype 149.04 ± 20.383
28-day dosing schedule: Week 16: Serotype 1411.88 ± 29.791
21-day dosing schedule: Week 18: Serotype 146.11 ± 3.302
28-day dosing schedule: Week 32: Serotype 1411.96 ± 26.509
21-day dosing schedule: Week 30: Serotype 145.76 ± 2.752
28-day dosing schedule: Week 48: Serotype 1413.02 ± 34.794
21-day dosing schedule: Week 48: Serotype 146.14 ± 3.408
Baseline: Serotype 172.55 ± 4.249
28-day dosing schedule: Week 16: Serotype 172.08 ± 3.977
21-day dosing schedule: Week 18: Serotype 173.25 ± 3.146
28-day dosing schedule: Week 32: Serotype 171.89 ± 2.952
21-day dosing schedule: Week 30: Serotype 173.38 ± 4.058
28-day dosing schedule: Week 48: Serotype 171.76 ± 3.043
21-day dosing schedule: Week 48: Serotype 173.09 ± 3.111
Baseline: Serotype 193.71 ± 5.275
28-day dosing schedule: Week 16: Serotype 194.95 ± 8.597
21-day dosing schedule: Week 18: Serotype 193.20 ± 1.074
28-day dosing schedule: Week 32: Serotype 193.71 ± 4.200
21-day dosing schedule: Week 30: Serotype 192.88 ± 0.686
28-day dosing schedule: Week 48: Serotype 194.25 ± 7.328
21-day dosing schedule: Week 48: Serotype 192.86 ± 0.958
Baseline: Serotype 22.38 ± 2.294
28-day dosing schedule: Week 16: Serotype 22.04 ± 1.618
21-day dosing schedule: Week 18: Serotype 23.34 ± 3.701
28-day dosing schedule: Week 32: Serotype 22.11 ± 1.502
21-day dosing schedule: Week 30: Serotype 23.48 ± 4.071
28-day dosing schedule: Week 48: Serotype 22.01 ± 1.283
21-day dosing schedule: Week 48: Serotype 23.35 ± 3.342
Baseline: Serotype 202.71 ± 2.296
28-day dosing schedule: Week 16: Serotype 202.63 ± 3.007
21-day dosing schedule: Week 18: Serotype 203.05 ± 1.425
28-day dosing schedule: Week 32: Serotype 202.76 ± 3.153
21-day dosing schedule: Week 30: Serotype 203.16 ± 1.614
28-day dosing schedule: Week 48: Serotype 202.51 ± 2.779
21-day dosing schedule: Week 48: Serotype 203.05 ± 1.295
Baseline: Serotype 221.33 ± 1.968
28-day dosing schedule: Week 16: Serotype 220.84 ± 0.938
21-day dosing schedule: Week 18: Serotype 222.36 ± 3.554
28-day dosing schedule: Week 32: Serotype 220.83 ± 0.698
21-day dosing schedule: Week 30: Serotype 222.78 ± 4.627
28-day dosing schedule: Week 48: Serotype 220.88 ± 0.670
21-day dosing schedule: Week 48: Serotype 222.51 ± 3.652
Baseline: Serotype 231.65 ± 2.336
28-day dosing schedule: Week 16: Serotype 231.42 ± 2.501
21-day dosing schedule: Week 18: Serotype 231.28 ± 0.696
28-day dosing schedule: Week 32: Serotype 231.37 ± 2.064
21-day dosing schedule: Week 30: Serotype 231.34 ± 0.607
28-day dosing schedule: Week 48: Serotype 231.47 ± 2.270
21-day dosing schedule: Week 48: Serotype 231.50 ± 0.733
Baseline: Serotype 261.72 ± 1.910
28-day dosing schedule: Week 16: Serotype 261.32 ± 1.578
21-day dosing schedule: Week 18: Serotype 261.83 ± 2.050
28-day dosing schedule: Week 32: Serotype 261.36 ± 1.515
21-day dosing schedule: Week 30: Serotype 261.70 ± 1.505
28-day dosing schedule: Week 48: Serotype 261.39 ± 1.549
21-day dosing schedule: Week 48: Serotype 261.73 ± 1.482
Baseline: Serotype 32.41 ± 5.964
28-day dosing schedule: Week 16: Serotype 31.41 ± 2.362
21-day dosing schedule: Week 18: Serotype 34.74 ± 7.812
28-day dosing schedule: Week 32: Serotype 31.42 ± 2.526
21-day dosing schedule: Week 30: Serotype 34.24 ± 6.480
28-day dosing schedule: Week 48: Serotype 31.12 ± 1.287
21-day dosing schedule: Week 48: Serotype 34.69 ± 7.854
Baseline: Serotype 341.83 ± 2.663
28-day dosing schedule: Week 16: Serotype 341.34 ± 1.718
21-day dosing schedule: Week 18: Serotype 343.33 ± 4.843
28-day dosing schedule: Week 32: Serotype 341.30 ± 1.524
21-day dosing schedule: Week 30: Serotype 343.73 ± 6.610
28-day dosing schedule: Week 48: Serotype 341.35 ± 1.585
21-day dosing schedule: Week 48: Serotype 343.04 ± 4.276
Baseline: Serotype 40.88 ± 1.366
28-day dosing schedule: Week 16: Serotype 40.54 ± 0.896
21-day dosing schedule: Week 18: Serotype 40.57 ± 0.576
28-day dosing schedule: Week 32: Serotype 41.07 ± 1.292
21-day dosing schedule: Week 30: Serotype 40.66 ± 0.434
28-day dosing schedule: Week 48: Serotype 40.89 ± 1.187
21-day dosing schedule: Week 48: Serotype 40.68 ± 0.466
Baseline: Serotype 431.36 ± 0.713
28-day dosing schedule: Week 16: Serotype 431.07 ± 0.665
21-day dosing schedule: Week 18: Serotype 431.51 ± 0.645
28-day dosing schedule: Week 32: Serotype 431.08 ± 0.568
21-day dosing schedule: Week 30: Serotype 431.43 ± 0.468
28-day dosing schedule: Week 48: Serotype 431.12 ± 0.605
21-day dosing schedule: Week 48: Serotype 431.61 ± 0.482
Baseline: Serotype 53.64 ± 5.551
28-day dosing schedule: Week 16: Serotype 52.68 ± 3.650
21-day dosing schedule: Week 18: Serotype 56.56 ± 9.390
28-day dosing schedule: Week 32: Serotype 52.65 ± 3.081
21-day dosing schedule: Week 30: Serotype 56.51 ± 10.172
28-day dosing schedule: Week 48: Serotype 52.44 ± 3.145
21-day dosing schedule: Week 48: Serotype 55.41 ± 7.414
Baseline: Serotype 512.82 ± 5.468
28-day dosing schedule: Week 16: Serotype 511.66 ± 0.777
21-day dosing schedule: Week 18: Serotype 515.96 ± 8.691
28-day dosing schedule: Week 32: Serotype 511.65 ± 0.786
21-day dosing schedule: Week 30: Serotype 515.70 ± 7.914
28-day dosing schedule: Week 48: Serotype 511.58 ± 0.843
21-day dosing schedule: Week 48: Serotype 515.86 ± 8.456
Baseline: Serotype 543.04 ± 4.819
28-day dosing schedule: Week 16: Serotype 542.33 ± 2.575
21-day dosing schedule: Week 18: Serotype 545.04 ± 6.363
28-day dosing schedule: Week 32: Serotype 542.95 ± 5.542
21-day dosing schedule: Week 30: Serotype 544.86 ± 5.637
28-day dosing schedule: Week 48: Serotype 542.53 ± 3.181
21-day dosing schedule: Week 48: Serotype 544.13 ± 3.700
Baseline: Serotype 563.41 ± 8.495
28-day dosing schedule: Week 16: Serotype 562.55 ± 6.989
21-day dosing schedule: Week 18: Serotype 565.84 ± 9.970
28-day dosing schedule: Week 32: Serotype 562.17 ± 5.089
21-day dosing schedule: Week 30: Serotype 565.38 ± 8.242
28-day dosing schedule: Week 48: Serotype 562.54 ± 8.116
21-day dosing schedule: Week 48: Serotype 566.00 ± 10.338
Baseline: Serotype 575.73 ± 8.398
28-day dosing schedule: Week 16: Serotype 575.11 ± 8.435
21-day dosing schedule: Week 18: Serotype 5723.40 ± 48.403
28-day dosing schedule: Week 32: Serotype 575.46 ± 9.059
21-day dosing schedule: Week 30: Serotype 577.00 ± 10.268
28-day dosing schedule: Week 48: Serotype 575.31 ± 9.379
21-day dosing schedule: Week 48: Serotype 578.17 ± 12.789
Baseline: Serotype 681.08 ± 1.095
28-day dosing schedule: Week 16: Serotype 680.86 ± 0.567
21-day dosing schedule: Week 18: Serotype 681.66 ± 1.555
28-day dosing schedule: Week 32: Serotype 680.93 ± 0.918
21-day dosing schedule: Week 30: Serotype 681.36 ± 1.260
28-day dosing schedule: Week 48: Serotype 680.76 ± 0.524
21-day dosing schedule: Week 48: Serotype 681.33 ± 1.233
Baseline: Serotype 701.98 ± 2.911
28-day dosing schedule: Week 16: Serotype 701.43 ± 1.100
21-day dosing schedule: Week 18: Serotype 703.56 ± 5.360
28-day dosing schedule: Week 32: Serotype 701.53 ± 1.128
21-day dosing schedule: Week 30: Serotype 703.53 ± 5.776
28-day dosing schedule: Week 48: Serotype 701.48 ± 0.988
21-day dosing schedule: Week 48: Serotype 703.19 ± 3.978
Baseline: Serotype 82.10 ± 2.650
28-day dosing schedule: Week 16: Serotype 81.67 ± 1.258
21-day dosing schedule: Week 18: Serotype 83.51 ± 3.440
28-day dosing schedule: Week 32: Serotype 81.86 ± 1.822
21-day dosing schedule: Week 30: Serotype 83.66 ± 4.268
28-day dosing schedule: Week 48: Serotype 81.82 ± 1.593
21-day dosing schedule: Week 48: Serotype 83.63 ± 3.479
Baseline: Serotype 90.96 ± 0.694
28-day dosing schedule: Week 16: Serotype 90.77 ± 0.510
21-day dosing schedule: Week 18: Serotype 91.03 ± 0.560
28-day dosing schedule: Week 32: Serotype 90.81 ± 0.587
21-day dosing schedule: Week 30: Serotype 90.99 ± 0.503
28-day dosing schedule: Week 48: Serotype 90.75 ± 0.433
21-day dosing schedule: Week 48: Serotype 91.03 ± 0.486
SecondaryAnti-Measles Antibody Levels

The anti-measles antibody levels were collected and analyzed at a central laboratory.

Time frame:
Baseline, Weeks 16, 32 and 48 (28-day dosing schedule); Weeks 18, 30, 48 (21-day dosing schedule)

No measurements were reported for this outcome.

SecondaryAnti-Haemophilus Influenza Type B Antibody Levels

The anti-haemophilus influenza type B antibody levels were collected and analyzed at central laboratory.

Time frame:
Baseline, Weeks 16, 32 and 48 (28 -day dosing schedule); Weeks 18, 30, 48 (21-day dosing schedule)
Reported as:
Mean · micrograms per milliliter (mcg/mL)
Anti-Haemophilus Influenza Type B Antibody Levels
micrograms per milliliter (mcg/mL)Kedrion IVIG 10%
Baseline2.010 ± 1.1641
28-day dosing schedule: Week 162.547 ± 1.7879
21-day dosing schedule: Week 182.489 ± 0.9027
28-day dosing schedule: Week 322.277 ± 1.3112
21-day dosing schedule: Week 302.888 ± 0.8676
28-day dosing schedule: Week 482.183 ± 1.1944
21-day dosing schedule: Week 482.606 ± 0.8433
SecondaryIncidence Rate of Any Infection Other Than Acute Serious Bacterial Infections

Incidence rate was defined as the mean number of any infection other than acute serious bacterial infections (bacterial pneumonia, bacteraemia/sepsis, bacterial meningitis, visceral abscess, osteomyelitis/septic arthritis) per participant-year. Incidence rate of any infection other than acute bacterial serious infections collected by the participant/participants parent(s)/legal guardian(s) in the participant diary or during clinic visit was reported.

Time frame:
Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Reported as:
Mean · infections per participant year
Incidence Rate of Any Infection Other Than Acute Serious Bacterial Infections
infections per participant yearKedrion IVIG 10%
21-day dosing schedule4.4 ± 2.11
28-day dosing schedule1.6 ± 1.27
SecondaryDuration of Any Infection Other Than Acute Serious Bacterial Infections

Duration of any infection other than serious acute bacterial infections (in days) was calculated as date of stop of infection - date of start of infection + 1. Duration of any infection other than serious acute bacterial infections collected by the by the participant/participants parent(s)/legal guardian(s) in the participant diary or during clinic visit was reported.

Time frame:
Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Reported as:
Mean · days
Duration of Any Infection Other Than Acute Serious Bacterial Infections
daysKedrion IVIG 10%
21-day dosing schedule41.0 ± 65.14
28-day dosing schedule24.9 ± 51.36
SecondaryIncidence Rate of Fever Episodes

Incidence rate was defined as the mean number of fever episodes per participant-year. Incidence rate of fever episodes collected by the participant/participant's parent(s)/legal guardian(s) in the participant diary or during clinic visit were reported.

Time frame:
Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Reported as:
Mean · fever episodes per participant year
Incidence Rate of Fever Episodes
fever episodes per participant yearKedrion IVIG 10%
21-day dosing schedule0.0 ± 0.0
28-day dosing schedule0.2 ± 0.42
SecondaryDuration of Fever Episodes in Participants

Duration of fever episodes in participants was reported.

Time frame:
Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Reported as:
Mean · days
Duration of Fever Episodes in Participants
daysKedrion IVIG 10%
28-day dosing schedule3.0 ± 2.24
SecondaryDuration of Overall Participants Hospitalization

Duration of overall participants hospitalization was reported.

Time frame:
Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Reported as:
Mean · days
Duration of Overall Participants Hospitalization
daysKedrion IVIG 10%
21-day dosing schedule6.0
28-day dosing schedule3.3 ± 1.53
SecondaryDuration of Participants Hospitalization Due to Infection

Duration of participants hospitalization due to infection was reported.

Time frame:
Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Reported as:
Mean

No measurements were reported for this outcome.

SecondaryIncidence Rate of Antibiotics Episodes for Treatment of Any Kind of Infections

Incidence rate was defined as the mean number of antibiotics episodes per participant year. Incidence rate of participants on antibiotics for treatment of any kind of infections was reported.

Time frame:
Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Reported as:
Mean · antibiotics episodes/participant year
Incidence Rate of Antibiotics Episodes for Treatment of Any Kind of Infections
antibiotics episodes/participant yearKedrion IVIG 10%
21-day dosing schedule3.8 ± 1.95
28-day dosing schedule2.1 ± 1.46
SecondaryDuration of Participants on Antibiotics for Treatment of Any Kind of Infection

Duration of participants on antibiotics for treatment of any kind of infection was reported.

Time frame:
Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Reported as:
Mean · days
Duration of Participants on Antibiotics for Treatment of Any Kind of Infection
daysKedrion IVIG 10%
21-day dosing schedule13.1 ± 5.72
28-day dosing schedule13.3 ± 35.86
SecondaryDuration of Missed School/Work/Other Major Activities Due to Infections

Duration of missed school/work/other major activities due to infections was reported.

Time frame:
Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Reported as:
Mean · days
Duration of Missed School/Work/Other Major Activities Due to Infections
daysKedrion IVIG 10%
21-day dosing schedule25.3 ± 25.11
28-day dosing schedule4.7 ± 2.73
SecondaryPediatric Quality of Life Inventory (PedsQL) Score

23-item PedsQL generic core scales was a modular approach to measure health-related Quality of Life (QoL) in healthy children, adolescents and those with acute and chronic health conditions. The total scale score (23 items) consisted of Physical Health Summary Score (8 items) and Psychosocial Health SummaryScore (15 items). Physical health summary included Physical Functioning (8 items) and Psychosocial health summary score included Emotional Functioning (5 items), Social Functioning (5 items) and School Functioning (5 items). Items were scored on a 5 point Likert-type response scale: 0=never a problem; 1=almost never a problem; 2=sometimes a problem; 3=often a problem; and 4=almost always a problem). Once scored, items were reverse scored and linearly transformed to a 0-100 scale, where higher scores indicated better QoL. The overall range for total PedsQL score (23 items) was 0 to 100, with higher score indicated better QoL. Data for 18-25 years and \>25 years age group was reported.

Time frame:
Baseline, Week 24 (21-day dosing schedule and 28-day dosing schedule), Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Reported as:
Mean · score on a scale
Pediatric Quality of Life Inventory (PedsQL) Score
score on a scaleKedrion IVIG 10%
Baseline (18 to 25 years)87.5 ± 16.14
21-day dosing schedule: Week 24 (18 to 25 years)68.5
21-day dosing schedule: Week 51 (18 to 25 years)58.7
28-day dosing schedule: Week 24 (18 to 25 years)100.0
28-day dosing schedule: Week 52 (18 to 25 years)100.0
Baseline (> 25 years)76.2 ± 16.53
21-day dosing schedule: Week 24 (> 25 years)65.1 ± 15.92
21-day dosing schedule: Week 51 (> 25 years)70.3 ± 18.93
28-day dosing schedule: Week 24 (> 25 years)78.3 ± 17.02
28-day dosing schedule: Week 52 (> 25 years)77.8 ± 18.42
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

An adverse event (AE) was defined as any untoward medical occurrence in a participant administered a study drug which may or may not have a causal relationship with the study drug. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life- threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAE was defined as an AE with an onset that occurs after receiving study drug. Any TEAE included participants with both serious and non-serious TEAEs.

Time frame:
Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsKedrion IVIG 10%
Participants with TEAEs: 21-day dosing schedule:8
Participants with TEAEs: 28-day dosing schedule38
Participants with Serious TEAEs: 21-day dosing schedule1
Participants with Serious TEAEs: 28-day dosing schedule3
SecondaryNumber of TEAEs and Serious TEAEs

An adverse event (AE) was defined as any untoward medical occurrence in a participant administered a study drug which may or may not have a causal relationship with the study drug. A SAE was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life- threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. A TEAE was defined as an AE with an onset that occurs after receiving study drug. Number of TEAEs and Serious TEAEs were reported.

Time frame:
Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Reported as:
Number · adverse events
Number of TEAEs and Serious TEAEs
adverse eventsKedrion IVIG 10%
TEAEs: 21-day dosing schedule81
TEAEs: 28-day dosing schedule324
Serious TEAEs: 21-day dosing schedule1
Serious TEAEs: 28-day dosing schedule4
SecondaryNumber of Drug Related Infusion Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a participant administered a study drug which may or may not have a causal relationship with the study drug. Number of drug related infusion AEs were reported.

Time frame:
Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Reported as:
Number · adverse events
Number of Drug Related Infusion Adverse Events (AEs)
adverse eventsKedrion IVIG 10%
21-day dosing schedule3
28-day dosing schedule60
SecondaryPercentage of Participants Who Experienced at Least One Drug Related Infusion Adverse Events (AEs)

Percentage of participants who experienced at least one drug related infusion AEs were reported.

Time frame:
Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced at Least One Drug Related Infusion Adverse Events (AEs)
percentage of participantsKedrion IVIG 10%
21-day dosing schedule25.0
28-day dosing schedule43.6
SecondaryNumber of Infusions With Decreased Infusion Rate Due to Adverse Events (AEs)

Number of infusions with decreased infusion rate due to AEs were reported.

Time frame:
Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Reported as:
Count of units · Infusions
Number of Infusions With Decreased Infusion Rate Due to Adverse Events (AEs)
InfusionsKedrion IVIG 10%
21-day dosing schedule0
28-day dosing schedule9
SecondaryNumber of Infusions With One or More Infusion Associated Adverse Events (AEs)

The number of infusions with one or more infusion associated AEs were reported collectively for 21 and 28-day dosing schedule up to Week 52.

Time frame:
Baseline up to Week 52
Reported as:
Count of units · Infusions
Number of Infusions With One or More Infusion Associated Adverse Events (AEs)
InfusionsKedrion IVIG 10%
Number of Infusions With One or More Infusion Associated Adverse Events (AEs)80
SecondaryNumber of Participants With Clinically Significant Changes From Baseline in Vital Signs

Vital signs included body temperature, systolic and diastolic blood pressure, heart rate and weight. The systolic and diastolic blood pressure and pulse rate was measured after the participants have in a rested at least 3 minutes in seated position. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in vital signs were reported.

Time frame:
Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes From Baseline in Vital Signs
ParticipantsKedrion IVIG 10%
21-day dosing schedule0
28-day dosing schedule0
SecondaryNumber of Participants With Clinically Significant Changes From Baseline in Physical Examinations

Physical examination included the examination of general appearance, skin, neck, eyes, ears, nose, throat, cardiovascular assessment including rhythm, and presence of other cardiac abnormalities (for example gallops, murmurs, cardiomegaly), respiratory system, gastrointestinal system, genitourinary system and musculoskeletal system. Clinical significance was decided by the investigator. The number of participants with clinically significant changes from baseline in physical examination were reported.

Time frame:
Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes From Baseline in Physical Examinations
ParticipantsKedrion IVIG 10%
21-day dosing schedule0
28-day dosing schedule0
SecondaryNumber of Participants With Clinically Significant Changes From Baseline in Laboratory Parameters

Laboratory parameters included chemistry, hematology and urinalysis. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in laboratory parameters were reported.

Time frame:
Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameters
ParticipantsKedrion IVIG 10%
Hematology: 21-day dosing schedule3
Hematology: 28-day dosing schedule7
Chemistry: 21-day dosing schedule1
Chemistry: 28-day dosing schedule5
Urinalysis: 21-day dosing schedule2
Urinalysis: 28-day dosing schedule4
SecondaryNumber of Participants With Positive Coomb's Test at Week 16 (28-day Dosing Schedule) and Week 18 (21-day Dosing Schedule)

Intravascular hemolysis testing was performed by using coomb's test. The coomb's assessment was performed at a central laboratory.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule)
Reported as:
Count of participants · Participants
Number of Participants With Positive Coomb's Test at Week 16 (28-day Dosing Schedule) and Week 18 (21-day Dosing Schedule)
ParticipantsKedrion IVIG 10%
28-day dosing schedule: Week 1614
21-day dosing schedule: Week 184
SecondaryNumber of Participants With Positive Urine Hemosiderin Test

Number of participants with positive urine hemosiderin test were reported.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule)
Reported as:
Count of participants · Participants
Number of Participants With Positive Urine Hemosiderin Test
ParticipantsKedrion IVIG 10%
28-day dosing schedule: Week 160
21-day dosing schedule: Week 180
SecondaryNumber of Participants With Abnormal Plasma-free Haemoglobin Level

Number of participants with plasma-free haemoglobin level more than or equal to (\>=) 69 milligrams per deciliter (mg/dL) were consisdered as abormal and were reported.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Plasma-free Haemoglobin Level
ParticipantsKedrion IVIG 10%
28-day dosing schedule: Week 1610
21-day dosing schedule : Week 182
SecondaryNumber of Participants With Abnormal Serum Haptoglobin Level

Number of participants with abnormal serum haptoglobin level were reported.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Serum Haptoglobin Level
ParticipantsKedrion IVIG 10%
28-day dosing schedule: Week 1610
21-day dosing schedule: Week 180
SecondaryMaximum Observed Serum Concentration (Cmax) of Total Immunoglobulin G (IgG)

Cmax was obtained directly from the concentration versus time curve. Both baseline corrected and un-corrected data was reported.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · milligrams per deciliter (mg/dL)
Maximum Observed Serum Concentration (Cmax) of Total Immunoglobulin G (IgG)
milligrams per deciliter (mg/dL)Kedrion IVIG 10%
Baseline corrected: 28-day dosing schedule: Week 161280 ± 433
Baseline corrected: 21-day dosing schedule: Week 181520 ± 185
Baseline uncorrected: 28-day dosing schedule: Week 162300 ± 466
Baseline uncorrected: 21-day dosing schedule: Week 182680 ± 282
SecondaryElimination Half-Life (t1/2) of Total IgG

t1/2 was the time measured for the concentration to decrease by one half. t1/2 was calculated by natural log 2 divided by Kel. Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase. Both baseline corrected and un-corrected data was reported.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · hours
Elimination Half-Life (t1/2) of Total IgG
hoursKedrion IVIG 10%
Baseline corrected: 28-day dosing schedule: Week 16158 ± 48.4
Baseline corrected: 21-day dosing schedule: Week 18107 ± 45.4
Baseline uncorrected: 28-day dosing schedule: Week 16896 ± 269
Baseline uncorrected: 21-day dosing schedule: Week 18587 ± 58.2
SecondaryArea Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of Total IgG

Area under the serum concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLOQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule. Both baseline corrected and un-corrected data was reported.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · day*milligram per deciliter (day*mg/dL)
Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of Total IgG
day*milligram per deciliter (day*mg/dL)Kedrion IVIG 10%
Baseline corrected: 28-day dosing schedule: Week 169520 ± 3310
Baseline corrected: 21-day dosing schedule: Week 188380 ± 1670
Baseline uncorrected: 28-day dosing schedule: Week 1637300 ± 7720
Baseline uncorrected: 21-day dosing schedule: Week 1831700 ± 6030
SecondaryArea Under the Serum Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Total IgG

AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Kel, where Clast pred was the calculated serum concentration at the last sampling time point at which the measured serum concentration is at or above the Lower Limit of quantification (LLOQ) and Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase. Both baseline corrected and un-corrected data was reported.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · hr*g/L
Area Under the Serum Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Total IgG
hr*g/LKedrion IVIG 10%
Baseline corrected: 28-day dosing schedule: Week 162710.991 ± 733.1555
Baseline corrected: 21-day dosing schedule: Week 182435.562 ± 471.842
Baseline uncorrected: 28-day dosing schedule: Week 1622065.3148 ± 5061.15798
Baseline uncorrected: 21-day dosing schedule: Week 1818292.68 ± 2869.244
SecondaryArea Under the Serum Concentration-Time Curve During a Dosing Interval (AUCtau) of Total IgG

AUCtau was defined as area under the serum concentration-time curve from time zero to the end of the dosing interval (tau). AUCtau was calculated using the mixed log linear trapezoidal rule. Both baseline corrected and un-corrected data was reported.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · day*mg/dL
Area Under the Serum Concentration-Time Curve During a Dosing Interval (AUCtau) of Total IgG
day*mg/dLKedrion IVIG 10%
Baseline corrected: 28-day dosing schedule: Week 169840 ± 3330
Baseline corrected: 21-day dosing schedule: Week 188860 ± 1630
Baseline uncorrected: 28-day dosing schedule: Week 1638000 ± 6500
Baseline uncorrected: 21-day dosing schedule: Week 1834000 ± 3630
SecondaryVolume of Distribution (Vd) of Total IgG

Vd was defined as the the theoretical volume in which the total amount of total IgG would need to be uniformly distributed to produce the desired blood concentration of a total IgG. Both baseline corrected and un-corrected data was reported.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · deciliters per kilogram (dL/kg)
Volume of Distribution (Vd) of Total IgG
deciliters per kilogram (dL/kg)Kedrion IVIG 10%
Baseline corrected: 28-day dosing schedule: Week 160.532 ± 0.108
Baseline corrected: 21-day dosing schedule: Week 180.563 ± 0.161
Baseline uncorrected: 28-day dosing schedule: Week 160.697 ± 0.118
Baseline uncorrected: 21-day dosing schedule: Week 180.667 ± 0.0398
SecondarySteady State Clearance (CLss) of Total IgG

Clearance of a total IgG was a measure of the rate at which a total IgG is metabolized or eliminated by normal biological processes. CLss of total IgG was measured in milliliters per hour per kilogram (mL/hr/kg). Both baseline corrected and un-corrected data was reported.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · dL/day/kg
Steady State Clearance (CLss) of Total IgG
dL/day/kgKedrion IVIG 10%
Baseline corrected: 28-day dosing schedule: Week 160.0559 ± 0.0102
Baseline corrected: 21-day dosing schedule: Week 180.0763 ± 0.00342
Baseline uncorrected: 28-day dosing schedule: Week 160.0140 ± 0.00355
Baseline uncorrected: 21-day dosing schedule: Week 180.0193 ± 0.00305
SecondaryMinimum Observed Serum Concentration (Cmin) of Total IgG

Cmin was minimum observed serum concentration obtained directly from the concentration versus time curve. Both baseline corrected and un-corrected data was reported.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · mg/dL
Minimum Observed Serum Concentration (Cmin) of Total IgG
mg/dLKedrion IVIG 10%
Baseline corrected: 28-day dosing schedule: Week 160.00 ± 0.00
Baseline corrected: 21-day dosing schedule: Week 180.00 ± 0.00
Baseline uncorrected: 28-day dosing schedule: Week 16994 ± 200
Baseline uncorrected: 21-day dosing schedule: Week 181140 ± 150
SecondaryTime to Reach the Maximum Serum Concentration (Tmax) of Total IgG

Tmax was obtained directly from the concentration versus time curve. Both baseline corrected and un-corrected data was reported.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Median · hours
Time to Reach the Maximum Serum Concentration (Tmax) of Total IgG
hoursKedrion IVIG 10%
Baseline corrected: 28-day dosing schedule: Week 160.515 (0.500 to 23.8)
Baseline corrected: 21-day dosing schedule: Week 180.530 (0.500 to 2.02)
Baseline uncorrected: 28-day dosing schedule: Week 160.515 (0.500 to 23.8)
Baseline uncorrected: 21-day dosing schedule: Week 180.530 (0.500 to 2.02)
SecondaryElimination Rate Constant (Kel) of Total IgG

Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase. Both baseline corrected and un-corrected data was reported.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · 1/hour
Elimination Rate Constant (Kel) of Total IgG
1/hourKedrion IVIG 10%
Baseline corrected: 28-day dosing schedule: Week 160.0048 ± 0.00156
Baseline corrected: 21-day dosing schedule: Week 180.00743 ± 0.00300
Baseline uncorrected: 28-day dosing schedule: Week 160.000845 ± 0.000270
Baseline uncorrected: 21-day dosing schedule: Week 180.00119 ± 0.000117
SecondaryAverage Concentration of Total IgG Over the Dosing Interval (Cavg)

Average concentration of total IgG over the dosing interval (Cavg) was reported. Both baseline corrected and un-corrected data was reported.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · mg/dL
Average Concentration of Total IgG Over the Dosing Interval (Cavg)
mg/dLKedrion IVIG 10%
Baseline corrected: 28-day dosing schedule: Week 16354 ± 117
Baseline corrected: 21-day dosing schedule: Week 18424 ± 78.6
Baseline uncorrected: 28-day dosing schedule: Week 161370 ± 239
Baseline uncorrected: 21-day dosing schedule: Week 181630 ± 175
SecondaryPercentage Peak Trough Fluctuation of Total IgG

The peak trough fluctuation within complete dosing interval at steady state of total IgG was reported. Both baseline corrected and un-corrected data was reported.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · percent fluctuation
Percentage Peak Trough Fluctuation of Total IgG
percent fluctuationKedrion IVIG 10%
Baseline corrected: 28-day dosing schedule: Week 16364 ± 70.7
Baseline corrected: 21-day dosing schedule: Week 18360 ± 56.3
Baseline uncorrected: 28-day dosing schedule: Week 1694.3 ± 30.6
Baseline uncorrected: 21-day dosing schedule: Week 1895.0 ± 7.92
SecondaryMaximum Observed Serum Concentration (Cmax) of Antigen-Specific Tetanus Toxoid Antibodies

Cmax was obtained directly from the concentration versus time curve.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · IU/mL
Maximum Observed Serum Concentration (Cmax) of Antigen-Specific Tetanus Toxoid Antibodies
IU/mLKedrion IVIG 10%
28-day dosing schedule: Week 166.533 ± 2.9955
21-day dosing schedule: Week 187.400 ± 2.0988
SecondaryElimination Half-Life (t1/2) of Antigen-Specific Tetanus Toxoid Antibodies

t1/2 was the time measured for the concentration to decrease by one half. t1/2 was calculated by natural log 2 divided by Kel. Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · hours
Elimination Half-Life (t1/2) of Antigen-Specific Tetanus Toxoid Antibodies
hoursKedrion IVIG 10%
28-day dosing schedule: Week 16618.97 ± 320.008
21-day dosing schedule: Week 181097.75 ± 1061.343
SecondaryArea Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of Antigen-Specific Tetanus Toxoid Antibodies

Area under the serum concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLOQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule. The AUC0-t of antigen-specific tetanus toxoid antibodies was measured in hour\*international units per milliliter (hr\*IU/mL).

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · hr*IU/mL
Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of Antigen-Specific Tetanus Toxoid Antibodies
hr*IU/mLKedrion IVIG 10%
28-day dosing schedule: Week 162037.7497 ± 568.85079
21-day dosing schedule: Week 181805.9758 ± 210.37005
SecondaryArea Under the Serum Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Antigen-Specific Tetanus Toxoid Antibodies

AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Kel, where Clast pred was the calculated serum concentration at the last sampling time point at which the measured serum concentration is at or above the Lower Limit of quantification (LLOQ) and Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · hour*microgram per milliliter(hr*mcg/mL)
Area Under the Serum Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Antigen-Specific Tetanus Toxoid Antibodies
hour*microgram per milliliter(hr*mcg/mL)Kedrion IVIG 10%
28-day dosing schedule: Week 164171.4977 ± 2513.60199
21-day dosing schedule: Week 1810142.0162 ± 12855.54687
SecondaryArea Under the Serum Concentration-Time Curve During a Dosing Interval (AUCtau) of Antigen-Specific Tetanus Toxoid Antibodies

AUCtau was defined as area under the serum concentration-time curve from time zero to the end of the dosing interval (tau). AUCtau was calculated using the mixed log linear trapezoidal rule.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · hr*IU/mL
Area Under the Serum Concentration-Time Curve During a Dosing Interval (AUCtau) of Antigen-Specific Tetanus Toxoid Antibodies
hr*IU/mLKedrion IVIG 10%
28-day dosing schedule: Week 161997.8829 ± 526.07254
21-day dosing schedule: Week 181934.6533 ± 317.07241
SecondaryVolume of Distribution (Vd) of Antigen-Specific Tetanus Toxoid Antibodies

Vd was defined as the the theoretical volume in which the total amount of antigen-specific tetanus toxoid antibodies would need to be uniformly distributed to produce the desired blood concentration of antigen-specific tetanus toxoid antibodies. The Vd of antigen-specific tetanus toxoid antibodies was measured in milligrams\*milliliter per international unit\*kilogram (mg\*mL/IU\*kg).

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · mg*mL/IU*kg
Volume of Distribution (Vd) of Antigen-Specific Tetanus Toxoid Antibodies
mg*mL/IU*kgKedrion IVIG 10%
28-day dosing schedule: Week 16263.3132 ± 157.80776
21-day dosing schedule: Week 18688.4792 ± 792.01235
SecondarySteady State Clearance (CLss) of Antigen-Specific Tetanus Toxoid Antibodies

Clearance of a antigen-specific tetanus toxoid antibodies was a measure of the rate at which a antigen-specific tetanus toxoid antibodies are metabolized or eliminated by normal biological processes. The CLss of antigen-specific tetanus toxoid antibodies was reported. The CLss of antigen-specific tetanus toxoid antibodies was measured in milligrams\*milliliter per hour\*international unit\*kilogram (mg\*mL/hr\*IU\*kg).

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · mg*mL/hr*IU*kg
Steady State Clearance (CLss) of Antigen-Specific Tetanus Toxoid Antibodies
mg*mL/hr*IU*kgKedrion IVIG 10%
28-day dosing schedule: Week 160.2741 ± 0.06916
21-day dosing schedule: Week 180.3724 ± 0.05201
SecondaryMinimum Observed Serum Concentration (Cmin) of Antigen-Specific Tetanus Toxoid Antibodies

Cmin was minimum observed serum concentration obtained directly from the concentration versus time curve.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · IU/mL
Minimum Observed Serum Concentration (Cmin) of Antigen-Specific Tetanus Toxoid Antibodies
IU/mLKedrion IVIG 10%
28-day dosing schedule: Week 161.833 ± 0.5531
21-day dosing schedule: Week 182.240 ± 0.4827
SecondaryTime to Reach the Maximum Serum Concentration (Tmax) of Antigen-Specific Tetanus Toxoid Antibodies

Tmax was obtained directly from the concentration versus time curve.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Median · hours
Time to Reach the Maximum Serum Concentration (Tmax) of Antigen-Specific Tetanus Toxoid Antibodies
hoursKedrion IVIG 10%
28-day dosing schedule: Week 162.000 (0.48 to 168.00)
21-day dosing schedule: Week 1870.450 (1.97 to 71.25)
SecondaryElimination Rate Constant (Kel) of Antigen-Specific Tetanus Toxoid Antibodies

Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · 1/hour
Elimination Rate Constant (Kel) of Antigen-Specific Tetanus Toxoid Antibodies
1/hourKedrion IVIG 10%
28-day dosing schedule: Week 160.0014 ± 0.00062
21-day dosing schedule: Week 180.0011 ± 0.00065
SecondaryAverage Concentration of Antigen-Specific Tetanus Toxoid Antibodies Over the Dosing Interval (Cavg)

Average concentration of antigen-specific tetanus toxoid antibodies over the dosing interval (Cavg) was reported.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · IU/mL
Average Concentration of Antigen-Specific Tetanus Toxoid Antibodies Over the Dosing Interval (Cavg)
IU/mLKedrion IVIG 10%
28-day dosing schedule: Week 162.9730 ± 0.78285
21-day dosing schedule: Week 183.8386 ± 0.62911
SecondaryPercentage Peak Trough Fluctuation of Antigen-Specific Tetanus Toxoid Antibodies

The peak trough fluctuation within complete dosing interval at steady state of antigen-specific tetanus toxoid antibodies was reported.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · percent fluctuation
Percentage Peak Trough Fluctuation of Antigen-Specific Tetanus Toxoid Antibodies
percent fluctuationKedrion IVIG 10%
28-day dosing schedule: Week 16154.7237 ± 63.56527
21-day dosing schedule: Week 18145.9127 ± 55.92179
SecondaryMaximum Observed Serum Concentration (Cmax) of Antigen-Specific Haemophilus Influenza Type B Antibodies

Cmax was obtained directly from the concentration versus time curve.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · milligram per deciliter (mg/dL)
Maximum Observed Serum Concentration (Cmax) of Antigen-Specific Haemophilus Influenza Type B Antibodies
milligram per deciliter (mg/dL)Kedrion IVIG 10%
28-day dosing schedule: Week 160.682 ± 0.204
21-day dosing schedule: Week 180.787 ± 0.141
SecondaryElimination Half-Life (t1/2) of Antigen-Specific Haemophilus Influenza Type B Antibodies

t1/2 was the time measured for the concentration to decrease by one half. t1/2 was calculated by natural log 2 divided by Kel. Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · hours
Elimination Half-Life (t1/2) of Antigen-Specific Haemophilus Influenza Type B Antibodies
hoursKedrion IVIG 10%
28-day dosing schedule: Week 16682 ± 488
21-day dosing schedule: Week 18364 ± 52.2
SecondaryArea Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of Antigen-Specific Haemophilus Influenza Type B Antibodies

Area under the serum concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLOQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule. AUC0-t of antigen-specific haemophilus influenza Type B Antibodies was measured in hour\*microgram per milliliter (hr\*mcg/mL).

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · day*mg/dL
Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of Antigen-Specific Haemophilus Influenza Type B Antibodies
day*mg/dLKedrion IVIG 10%
28-day dosing schedule: Week 169.80 ± 4.35
21-day dosing schedule: Week 188.80 ± 3.02
SecondaryArea Under the Serum Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Antigen-Specific Haemophilus Influenza Type B Antibodies

AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Kel, where Clast pred was the calculated serum concentration at the last sampling time point at which the measured serum concentration is at or above the Lower Limit of quantification (LLOQ) and Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · hr*mcg/mL
Area Under the Serum Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Antigen-Specific Haemophilus Influenza Type B Antibodies
hr*mcg/mLKedrion IVIG 10%
28-day dosing schedule: Week 165087.4141 ± 3563.09258
21-day dosing schedule: Week 184223.1698 ± 493.35835
SecondaryArea Under the Serum Concentration-Time Curve During a Dosing Interval (AUCtau) of Antigen-Specific Haemophilus Influenza Type B Antibodies

AUCtau was defined as area under the serum concentration-time curve from time zero to the end of the dosing interval (tau). AUCtau was calculated using the mixed log linear trapezoidal rule.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · day*mg/dL
Area Under the Serum Concentration-Time Curve During a Dosing Interval (AUCtau) of Antigen-Specific Haemophilus Influenza Type B Antibodies
day*mg/dLKedrion IVIG 10%
28-day dosing schedule: Week 169.80 ± 4.35
21-day dosing schedule: Week 189.90 ± 2.03
SecondaryVolume of Distribution (Vd) of Antigen-Specific Haemophilus Influenza Type B Antibodies

Vd was defined as the the theoretical volume in which the total amount of antigen-specific haemophilus influenza type B antibodies would need to be uniformly distributed to produce the desired blood concentration of a antigen-specific haemophilus influenza type B antibodies.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · milligrams per kilogram (mL/kg)
Volume of Distribution (Vd) of Antigen-Specific Haemophilus Influenza Type B Antibodies
milligrams per kilogram (mL/kg)Kedrion IVIG 10%
28-day dosing schedule: Week 16245966.4231 ± 160457.69395
21-day dosing schedule: Week 18182273.0408 ± 88143.84190
SecondarySteady State Clearance (CLss) of Antigen-Specific Haemophilus Influenza Type B Antibodies

Clearance of antigen-specific haemophilus influenza type B antibodies was a measure of the rate at which antigen-specific haemophilus influenza type B antibodies were metabolized or eliminated by normal biological processes. CLss of antigen-specific haemophilus influenza type B antibodies was measured in milliliter per hour per kilogram (mL/hr/kg).

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · mL/hr/kg
Steady State Clearance (CLss) of Antigen-Specific Haemophilus Influenza Type B Antibodies
mL/hr/kgKedrion IVIG 10%
28-day dosing schedule: Week 16253.5539 ± 75.88763
21-day dosing schedule: Week 18299.5030 ± 100.44087
SecondaryMinimum Observed Serum Concentration (Cmin) of Antigen-Specific Haemophilus Influenza Type B Antibodies

Cmin was minimum observed serum concentration obtained directly from the concentration versus time curve.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · mg/dL
Minimum Observed Serum Concentration (Cmin) of Antigen-Specific Haemophilus Influenza Type B Antibodies
mg/dLKedrion IVIG 10%
28-day dosing schedule: Week 160.215 ± 0.134
21-day dosing schedule: Week 180.225 ± 0.0623
SecondaryTime to Reach the Maximum Serum Concentration (Tmax) of Antigen-Specific Haemophilus Influenza Type B Antibodies

Tmax was obtained directly from the concentration versus time curve.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Median · hours
Time to Reach the Maximum Serum Concentration (Tmax) of Antigen-Specific Haemophilus Influenza Type B Antibodies
hoursKedrion IVIG 10%
28-day dosing schedule: Week 160.500 (0.480 to 24.3)
21-day dosing schedule: Week 182.02 (0.500 to 502)
SecondaryTerminal Elimination Rate Constant (Lambda z) of Antigen-Specific Haemophilus Influenza Type B Antibodies

Terminal Elimination Rate Constant (lambda z) derived if data allowed based on PK acceptance criteria

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · 1/hour
Terminal Elimination Rate Constant (Lambda z) of Antigen-Specific Haemophilus Influenza Type B Antibodies
1/hourKedrion IVIG 10%
28-day dosing schedule: Week 160.00148 ± 0.000815
21-day dosing schedule: Week 180.00192 ± 0.000276
SecondaryAverage Concentration of Antigen-Specific Haemophilus Influenza Type B Antibodies Over the Dosing Interval (Cavg)

Average concentration of antigen-specific haemophilus influenza type B antibodies over the dosing interval (Cavg) was reported.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · mg/dL
Average Concentration of Antigen-Specific Haemophilus Influenza Type B Antibodies Over the Dosing Interval (Cavg)
mg/dLKedrion IVIG 10%
28-day dosing schedule: Week 160.352 ± 0.155
21-day dosing schedule: Week 180.474 ± 0.0971
SecondaryPercentage Peak Trough Fluctuation of Antigen-Specific Haemophilus Influenza Type B Antibodies

The peak trough fluctuation within complete dosing interval at steady state of antigen-specific haemophilus influenza type B antibodies was reported.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · percent fluctuation
Percentage Peak Trough Fluctuation of Antigen-Specific Haemophilus Influenza Type B Antibodies
percent fluctuationKedrion IVIG 10%
28-day dosing schedule: Week 16141 ± 72.8
21-day dosing schedule: Week 1888.1 ± 66.9
SecondaryMaximum Observed Serum Concentration (Cmax) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)

Cmax was obtained directly from the concentration versus time curve. The Cmax for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8, serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · mg/L
Maximum Observed Serum Concentration (Cmax) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)
mg/LKedrion IVIG 10%
28-day dosing schedule: Week 16: Serotype 13.478 ± 2.7623
28-day dosing schedule: Week 16: Serotype 121.256 ± 1.2458
28-day dosing schedule: Week 16: Serotype 1420.378 ± 46.3772
28-day dosing schedule: Week 16: Serotype 174.350 ± 5.6783
28-day dosing schedule: Week 16: Serotype 197.767 ± 8.5255
28-day dosing schedule: Week 16: Serotype 23.822 ± 1.2758
28-day dosing schedule: Week 16: Serotype 204.728 ± 3.0665
28-day dosing schedule: Week 16: Serotype 222.050 ± 1.3382
28-day dosing schedule: Week 16: Serotype 233.039 ± 3.3482
28-day dosing schedule: Week 16: Serotype 262.433 ± 1.3569
28-day dosing schedule: Week 16: Serotype 32.933 ± 1.6150
28-day dosing schedule: Week 16: Serotype 40.685 ± 0.2410
28-day dosing schedule: Week 16: Serotype 342.472 ± 0.9940
28-day dosing schedule: Week 16: Serotype 432.572 ± 1.1108
28-day dosing schedule: Week 16: Serotype 55.217 ± 4.0965
28-day dosing schedule: Week 16: Serotype 513.611 ± 1.3788
28-day dosing schedule: Week 16: Serotype 544.806 ± 2.0783
28-day dosing schedule: Week 16: Serotype 565.778 ± 11.7004
28-day dosing schedule: Week 16: Serotype 5712.511 ± 21.4792
28-day dosing schedule: Week 16: Serotype 681.806 ± 0.8033
28-day dosing schedule: Week 16: Serotype 703.228 ± 1.6080
28-day dosing schedule: Week 16: Serotype 83.683 ± 2.6600
28-day dosing schedule: Week 16: Serotype 91.583 ± 0.7148
21-day dosing schedule: Week 18: Serotype 18.440 ± 8.3182
21-day dosing schedule: Week 18: Serotype 121.140 ± 0.1673
21-day dosing schedule: Week 18: Serotype 1411.280 ± 3.5053
21-day dosing schedule: Week 18: Serotype 175.860 ± 4.0930
21-day dosing schedule: Week 18: Serotype 196.440 ± 1.0691
21-day dosing schedule: Week 18: Serotype 26.180 ± 4.6370
21-day dosing schedule: Week 18: Serotype 205.580 ± 1.8754
21-day dosing schedule: Week 18: Serotype 224.420 ± 5.4422
21-day dosing schedule: Week 18: Serotype 232.360 ± 0.8620
21-day dosing schedule: Week 18: Serotype 263.340 ± 2.5373
21-day dosing schedule: Week 18: Serotype 39.720 ± 12.7874
21-day dosing schedule: Week 18: Serotype 345.060 ± 6.2843
21-day dosing schedule: Week 18: Serotype 40.980 ± 0.6301
21-day dosing schedule: Week 18: Serotype 432.660 ± 0.7403
21-day dosing schedule: Week 18: Serotype 510.160 ± 12.4969
21-day dosing schedule: Week 18: Serotype 5111.700 ± 14.2886
21-day dosing schedule: Week 18: Serotype 549.820 ± 10.6338
21-day dosing schedule: Week 18: Serotype 5613.300 ± 19.3380
21-day dosing schedule: Week 18: Serotype 575.825 ± 0.9878
21-day dosing schedule: Week 18: Serotype 682.460 ± 1.7009
21-day dosing schedule: Week 18: Serotype 706.260 ± 7.0741
21-day dosing schedule: Week 18: Serotype 86.120 ± 4.5510
21-day dosing schedule: Week 18: Serotype 91.980 ± 0.7294
SecondaryElimination Half-Life (t1/2) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)

t1/2 was the time measured for the concentration to decrease by one half. t1/2 was calculated by natural log 2 divided by Kel. Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase.Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase. The t1/2 for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · hours
Elimination Half-Life (t1/2) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)
hoursKedrion IVIG 10%
28-day dosing schedule: Week 16: Serotype 1533.06 ± 279.860
28-day dosing schedule: Week 16: Serotype 12415.27 ± 104.179
28-day dosing schedule: Week 16: Serotype 14737.33 ± 293.005
28-day dosing schedule: Week 16: Serotype 17568.11 ± 184.079
28-day dosing schedule: Week 16: Serotype 19794.76 ± 365.625
28-day dosing schedule: Week 16: Serotype 2943.63 ± 597.812
28-day dosing schedule: Week 16: Serotype 20977.87 ± 511.568
28-day dosing schedule: Week 16: Serotype 22574.22 ± 258.366
28-day dosing schedule: Week 16: Serotype 23837.29 ± 476.321
28-day dosing schedule: Week 16: Serotype 26638.60 ± 285.966
28-day dosing schedule: Week 16: Serotype 3626.69 ± 275.200
28-day dosing schedule: Week 16: Serotype 34680.14 ± 400.291
28-day dosing schedule: Week 16: Serotype 4522.15 ± 39.466
28-day dosing schedule: Week 16: Serotype 43573.32 ± 191.776
28-day dosing schedule: Week 16: Serotype 5632.03 ± 220.955
28-day dosing schedule: Week 16: Serotype 51794.63 ± 474.015
28-day dosing schedule: Week 16: Serotype 541184.97 ± 1088.054
28-day dosing schedule: Week 16: Serotype 56527.75 ± 144.729
28-day dosing schedule: Week 16: Serotype 571346.21 ± 1574.359
28-day dosing schedule: Week 16: Serotype 68688.31 ± 354.982
28-day dosing schedule: Week 16: Serotype 70709.41 ± 282.061
28-day dosing schedule: Week 16: Serotype 8562.30 ± 138.178
28-day dosing schedule: Week 16: Serotype 9555.66 ± 274.555
21-day dosing schedule: Week 18: Serotype 1813.74
21-day dosing schedule: Week 18: Serotype 12498.21 ± 105.271
21-day dosing schedule: Week 18: Serotype 141467.24
21-day dosing schedule: Week 18: Serotype 171161.62 ± 409.606
21-day dosing schedule: Week 18: Serotype 19839.73 ± 867.812
21-day dosing schedule: Week 18: Serotype 2860.60
21-day dosing schedule: Week 18: Serotype 20779.88
21-day dosing schedule: Week 18: Serotype 22966.61 ± 104.462
21-day dosing schedule: Week 18: Serotype 23805.76 ± 155.609
21-day dosing schedule: Week 18: Serotype 26900.44
21-day dosing schedule: Week 18: Serotype 3292.95
21-day dosing schedule: Week 18: Serotype 34820.04 ± 92.314
21-day dosing schedule: Week 18: Serotype 4638.35 ± 549.756
21-day dosing schedule: Week 18: Serotype 43295.34 ± 120.334
21-day dosing schedule: Week 18: Serotype 5825.99
21-day dosing schedule: Week 18: Serotype 51813.32
21-day dosing schedule: Week 18: Serotype 54754.20
21-day dosing schedule: Week 18: Serotype 56931.50
21-day dosing schedule: Week 18: Serotype 68259.63
21-day dosing schedule: Week 18: Serotype 701437.71 ± 1083.055
21-day dosing schedule: Week 18: Serotype 8616.54
21-day dosing schedule: Week 18: Serotype 9890.30
SecondaryArea Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)

Area under the serum concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLOQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule. AUC0-t of antigen-pneumococcal capsular polysaccharide was measured in hour\*microgram per milliliter (hr\*mcg/mL). The AUC0-t for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · hr*mg/L
Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)
hr*mg/LKedrion IVIG 10%
28-day dosing schedule: Week 16: Serotype 11267.2703 ± 1231.86109
28-day dosing schedule: Week 16: Serotype 12481.8080 ± 615.13837
28-day dosing schedule: Week 16: Serotype 147680.6757 ± 17443.37339
28-day dosing schedule: Week 16: Serotype 171707.2987 ± 2326.27590
28-day dosing schedule: Week 16: Serotype 193264.5178 ± 4922.67289
28-day dosing schedule: Week 16: Serotype 21462.1037 ± 491.94211
28-day dosing schedule: Week 16: Serotype 201776.5915 ± 1472.71297
28-day dosing schedule: Week 16: Serotype 22767.3831 ± 752.08067
28-day dosing schedule: Week 16: Serotype 231206.7604 ± 1547.47617
28-day dosing schedule: Week 16: Serotype 26929.6216 ± 696.05624
28-day dosing schedule: Week 16: Serotype 3940.1352 ± 397.58653
28-day dosing schedule: Week 16: Serotype 34916.8877 ± 339.74807
28-day dosing schedule: Week 16: Serotype 4245.8296 ± 89.81281
28-day dosing schedule: Week 16: Serotype 43901.9934 ± 415.28147
28-day dosing schedule: Week 16: Serotype 51882.0174 ± 1606.54653
28-day dosing schedule: Week 16: Serotype 511313.1756 ± 285.57756
28-day dosing schedule: Week 16: Serotype 541659.0010 ± 487.17054
28-day dosing schedule: Week 16: Serotype 562361.1009 ± 5435.67901
28-day dosing schedule: Week 16: Serotype 575140.5242 ± 10426.05050
28-day dosing schedule: Week 16: Serotype 68637.6826 ± 180.23219
28-day dosing schedule: Week 16: Serotype 701239.3842 ± 746.05163
28-day dosing schedule: Week 16: Serotype 81396.1732 ± 1343.80361
28-day dosing schedule: Week 16: Serotype 9545.3315 ± 201.37388
21-day dosing schedule: Week 18: Serotype 13361.3444 ± 3529.24121
21-day dosing schedule: Week 18: Serotype 12364.7574 ± 66.07380
21-day dosing schedule: Week 18: Serotype 144026.2582 ± 1827.76472
21-day dosing schedule: Week 18: Serotype 172327.4433 ± 1869.77732
21-day dosing schedule: Week 18: Serotype 192139.8818 ± 546.99394
21-day dosing schedule: Week 18: Serotype 22388.1819 ± 2054.90148
21-day dosing schedule: Week 18: Serotype 202088.0431 ± 956.15600
21-day dosing schedule: Week 18: Serotype 221728.1721 ± 2363.07921
21-day dosing schedule: Week 18: Serotype 23826.4154 ± 390.75602
21-day dosing schedule: Week 18: Serotype 261199.7678 ± 1115.65007
21-day dosing schedule: Week 18: Serotype 33834.6179 ± 5425.47048
21-day dosing schedule: Week 18: Serotype 342095.6088 ± 2982.98719
21-day dosing schedule: Week 18: Serotype 4363.5605 ± 289.99268
21-day dosing schedule: Week 18: Serotype 43919.1971 ± 290.08829
21-day dosing schedule: Week 18: Serotype 54050.8597 ± 5582.10279
21-day dosing schedule: Week 18: Serotype 514775.1477 ± 6034.17097
21-day dosing schedule: Week 18: Serotype 543849.0042 ± 4696.54103
21-day dosing schedule: Week 18: Serotype 565069.9328 ± 7483.01937
21-day dosing schedule: Week 18: Serotype 571946.7526 ± 134.44174
21-day dosing schedule: Week 18: Serotype 68900.2735 ± 757.57732
21-day dosing schedule: Week 18: Serotype 702385.0419 ± 3013.20369
21-day dosing schedule: Week 18: Serotype 82555.3317 ± 2162.87976
21-day dosing schedule: Week 18: Serotype 9707.9849 ± 310.25117
SecondaryArea Under the Serum Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)

AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Kel, where Clast pred was the calculated serum concentration at the last sampling time point at which the measured serum concentration is at or above the Lower Limit of quantification (LLOQ) and Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase. The AUC0-inf for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20 serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · hr*mg/L
Area Under the Serum Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)
hr*mg/LKedrion IVIG 10%
28-day dosing schedule: Week 16: Serotype 1835.7493
28-day dosing schedule: Week 16: Serotype 17815.5984
28-day dosing schedule: Week 16: Serotype 22706.0824 ± 101.30543
28-day dosing schedule: Week 16: Serotype 3753.3039
28-day dosing schedule: Week 16: Serotype 56871.0663
28-day dosing schedule: Week 16: Serotype 9494.5129
21-day dosing schedule: Week 18: Serotype 431072.8342
SecondaryArea Under the Serum Concentration-Time Curve During a Dosing Interval (AUCtau) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)

AUCtau was defined as area under the serum concentration-time curve from time zero to the end of the dosing interval (tau). AUCtau was calculated using the mixed log linear trapezoidal rule. The AUCtau for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · hr*mg/L
Area Under the Serum Concentration-Time Curve During a Dosing Interval (AUCtau) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)
hr*mg/LKedrion IVIG 10%
28-day dosing schedule: Week 16: Serotype 11295.2208 ± 1284.98717
28-day dosing schedule: Week 16: Serotype 12496.5246 ± 652.01919
28-day dosing schedule: Week 16: Serotype 147938.1617 ± 18005.53693
28-day dosing schedule: Week 16: Serotype 171128.6509 ± 606.69308
28-day dosing schedule: Week 16: Serotype 192051.7286 ± 805.43957
28-day dosing schedule: Week 16: Serotype 21437.7169 ± 551.52102
28-day dosing schedule: Week 16: Serotype 201738.1297 ± 1558.89268
28-day dosing schedule: Week 16: Serotype 22759.1847 ± 785.00558
28-day dosing schedule: Week 16: Serotype 231221.7947 ± 1608.36169
28-day dosing schedule: Week 16: Serotype 26929.6706 ± 739.10055
28-day dosing schedule: Week 16: Serotype 3902.9745 ± 415.50944
28-day dosing schedule: Week 16: Serotype 34879.5261 ± 347.31703
28-day dosing schedule: Week 16: Serotype 4241.3102 ± 93.08585
28-day dosing schedule: Week 16: Serotype 43934.7032 ± 507.01946
28-day dosing schedule: Week 16: Serotype 51525.6893 ± 617.53144
28-day dosing schedule: Week 16: Serotype 511327.8807 ± 304.68999
28-day dosing schedule: Week 16: Serotype 541665.6043 ± 473.20463
28-day dosing schedule: Week 16: Serotype 562456.3187 ± 5608.60157
28-day dosing schedule: Week 16: Serotype 575157.6297 ± 10068.88936
28-day dosing schedule: Week 16: Serotype 68646.0577 ± 303.83828
28-day dosing schedule: Week 16: Serotype 701242.0569 ± 791.72945
28-day dosing schedule: Week 16: Serotype 81112.3875 ± 364.77366
28-day dosing schedule: Week 16: Serotype 9549.2854 ± 205.21945
21-day dosing schedule: Week 18: Serotype 13427.1894 ± 4395.22135
21-day dosing schedule: Week 18: Serotype 12340.6625 ± 40.16239
21-day dosing schedule: Week 18: Serotype 144203.7328 ± 2074.59529
21-day dosing schedule: Week 18: Serotype 172120.4069 ± 1774.61729
21-day dosing schedule: Week 18: Serotype 192588.0431 ± 884.21458
21-day dosing schedule: Week 18: Serotype 21995.4796 ± 1312.64625
21-day dosing schedule: Week 18: Serotype 202571.9984 ± 1782.65587
21-day dosing schedule: Week 18: Serotype 22860.7046 ± 377.70459
21-day dosing schedule: Week 18: Serotype 231074.8702 ± 591.84867
21-day dosing schedule: Week 18: Serotype 261640.1471 ± 1585.98684
21-day dosing schedule: Week 18: Serotype 36340.4080 ± 9208.98601
21-day dosing schedule: Week 18: Serotype 34871.0315 ± 46.94825
21-day dosing schedule: Week 18: Serotype 4464.1417 ± 438.74819
21-day dosing schedule: Week 18: Serotype 43971.2482 ± 311.33350
21-day dosing schedule: Week 18: Serotype 51536.7299 ± 239.98044
21-day dosing schedule: Week 18: Serotype 515984.7197 ± 8063.82766
21-day dosing schedule: Week 18: Serotype 544422.4410 ± 5245.59189
21-day dosing schedule: Week 18: Serotype 566780.9969 ± 9967.85603
21-day dosing schedule: Week 18: Serotype 572280.6541 ± 245.58661
21-day dosing schedule: Week 18: Serotype 681209.1992 ± 1169.34365
21-day dosing schedule: Week 18: Serotype 701136.7545 ± 243.27839
21-day dosing schedule: Week 18: Serotype 82145.6232 ± 1950.12455
21-day dosing schedule: Week 18: Serotype 9764.0375 ± 331.36438
SecondaryVolume of Distribution (Vd) of of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)

Vd was defined as the the theoretical volume in which the total amount of anti-pneumococcal capsular polysaccharide would need to be uniformly distributed to produce the desired blood concentration of a anti-pneumococcal capsular polysaccharide. The Vd for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · mL/kg
Volume of Distribution (Vd) of of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)
mL/kgKedrion IVIG 10%
28-day dosing schedule: Week 16: Serotype 1329057.3200
28-day dosing schedule: Week 16: Serotype 17341197.1700
28-day dosing schedule: Week 16: Serotype 22231539.8050 ± 104298.38458
28-day dosing schedule: Week 16: Serotype 3226738.9500
28-day dosing schedule: Week 16: Serotype 56342896.0600
28-day dosing schedule: Week 16: Serotype 9526016.9000
21-day dosing schedule: Week 18: Serotype 43283171.4700
SecondarySteady State Clearance (CLss) of Anti-pneumococcal Capsular Polysaccharide Antibodies (Overall SP Serotypes)

Clearance of a anti-pneumococcal capsular polysaccharide antibodies was a measure of the rate at which a anti-pneumococcal capsular polysaccharide antibodies are metabolized or eliminated by normal biological processes. The CLss of anti-pneumococcal capsular polysaccharide antibodies was reported. The CLss of anti-pneumococcal capsular polysaccharide antibodies was measured in milligrams\*milliliter per hour\*international unit\*kilogram (mg\*mL/hr\*IU\*kg). The CLss for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · mg*mL/hr*IU*kg
Steady State Clearance (CLss) of Anti-pneumococcal Capsular Polysaccharide Antibodies (Overall SP Serotypes)
mg*mL/hr*IU*kgKedrion IVIG 10%
28-day dosing schedule: Week 16: Serotype 1860.4600
28-day dosing schedule: Week 16: Serotype 17862.3000
28-day dosing schedule: Week 16: Serotype 22604.0850 ± 190.31779
28-day dosing schedule: Week 16: Serotype 3705.5700
28-day dosing schedule: Week 16: Serotype 56854.8300
28-day dosing schedule: Week 16: Serotype 91441.7300
21-day dosing schedule: Week 18: Serotype 43849.0400
SecondaryMinimum Observed Serum Concentration (Cmin) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)

Cmin was minimum observed serum concentration obtained directly from the concentration versus time curve. The Cmin for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · mg/L
Minimum Observed Serum Concentration (Cmin) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)
mg/LKedrion IVIG 10%
28-day dosing schedule: Week 16: Serotype 11.167 ± 0.7577
28-day dosing schedule: Week 16: Serotype 120.528 ± 0.8259
28-day dosing schedule: Week 16: Serotype 148.361 ± 19.9012
28-day dosing schedule: Week 16: Serotype 172.328 ± 4.4311
28-day dosing schedule: Week 16: Serotype 193.783 ± 6.2568
28-day dosing schedule: Week 16: Serotype 21.656 ± 0.8487
28-day dosing schedule: Week 16: Serotype 201.689 ± 0.7522
28-day dosing schedule: Week 16: Serotype 220.817 ± 1.0257
28-day dosing schedule: Week 16: Serotype 231.228 ± 1.8588
28-day dosing schedule: Week 16: Serotype 260.978 ± 0.6804
28-day dosing schedule: Week 16: Serotype 30.950 ± 0.5924
28-day dosing schedule: Week 16: Serotype 341.033 ± 0.6903
28-day dosing schedule: Week 16: Serotype 40.277 ± 0.1235
28-day dosing schedule: Week 16: Serotype 430.983 ± 0.6600
28-day dosing schedule: Week 16: Serotype 52.306 ± 3.2598
28-day dosing schedule: Week 16: Serotype 511.406 ± 0.4771
28-day dosing schedule: Week 16: Serotype 541.733 ± 0.6598
28-day dosing schedule: Week 16: Serotype 562.750 ± 6.7280
28-day dosing schedule: Week 16: Serotype 575.422 ± 10.7795
28-day dosing schedule: Week 16: Serotype 680.728 ± 0.4390
28-day dosing schedule: Week 16: Serotype 701.350 ± 0.9931
28-day dosing schedule: Week 16: Serotype 81.294 ± 0.6476
28-day dosing schedule: Week 16: Serotype 90.517 ± 0.2550
21-day dosing schedule: Week 18 : Serotype 15.400 ± 6.4211
21-day dosing schedule: Week 18 : Serotype 120.440 ± 0.1817
21-day dosing schedule: Week 18 : Serotype 145.880 ± 4.0084
21-day dosing schedule: Week 18 : Serotype 173.700 ± 3.3978
21-day dosing schedule: Week 18 : Serotype 192.940 ± 1.3107
21-day dosing schedule: Week 18 : Serotype 23.600 ± 3.6159
21-day dosing schedule: Week 18 : Serotype 203.120 ± 1.8992
21-day dosing schedule: Week 18 : Serotype 222.520 ± 3.6486
21-day dosing schedule: Week 18 : Serotype 231.200 ± 0.8660
21-day dosing schedule: Week 18: Serotype 261.740 ± 1.9191
21-day dosing schedule: Week 18: Serotype 35.920 ± 8.6126
21-day dosing schedule: Week 18: Serotype 343.220 ± 5.0226
21-day dosing schedule: Week 18: Serotype 40.520 ± 0.5630
21-day dosing schedule: Week 18: Serotype 431.300 ± 0.8031
21-day dosing schedule: Week 18: Serotype 56.240 ± 9.6619
21-day dosing schedule: Week 18: Serotype 517.620 ± 10.4406
21-day dosing schedule: Week 18: Serotype 545.980 ± 8.1515
21-day dosing schedule: Week 18: Serotype 567.820 ± 12.0038
21-day dosing schedule: Week 18: Serotype 572.375 ± 0.5909
21-day dosing schedule: Week 18: Serotype 681.400 ± 1.5700
21-day dosing schedule: Week 18: Serotype 703.920 ± 5.6971
21-day dosing schedule: Week 18: Serotype 84.260 ± 4.2846
21-day dosing schedule: Week 18: Serotype 91.040 ± 0.6804
SecondaryTime to Reach the Maximum Serum Concentration (Tmax) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)

Tmax was obtained directly from the concentration versus time curve. The Tmax for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Median · hours
Time to Reach the Maximum Serum Concentration (Tmax) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)
hoursKedrion IVIG 10%
28-day dosing schedule: Week 16: Serotype 10.542 (0.48 to 529.75)
28-day dosing schedule: Week 16: Serotype 120.517 (0.48 to 529.75)
28-day dosing schedule: Week 16: Serotype 141.417 (0.48 to 529.75)
28-day dosing schedule: Week 16: Serotype 171.992 (0.48 to 529.75)
28-day dosing schedule: Week 16: Serotype 190.642 (0.48 to 529.75)
28-day dosing schedule: Week 16: Serotype 21.458 (0.48 to 529.75)
28-day dosing schedule: Week 16: Serotype 220.500 (0.48 to 529.75)
28-day dosing schedule: Week 16: Serotype 230.642 (0.48 to 529.75)
28-day dosing schedule: Week 16: Serotype 260.642 (0.48 to 529.75)
28-day dosing schedule: Week 16: Serotype 30.517 (0.48 to 529.75)
28-day dosing schedule: Week 16: Serotype 341.758 (0.48 to 529.75)
28-day dosing schedule: Week 16: Serotype 40.500 (0.48 to 24.10)
28-day dosing schedule: Week 16: Serotype 431.750 (0.48 to 529.75)
28-day dosing schedule: Week 16: Serotype 50.642 (0.48 to 529.75)
28-day dosing schedule: Week 16: Serotype 510.650 (0.48 to 529.75)
28-day dosing schedule: Week 16: Serotype 540.642 (0.48 to 529.75)
28-day dosing schedule: Week 16: Serotype 561.633 (0.48 to 529.75)
28-day dosing schedule: Week 16: Serotype 570.642 (0.48 to 529.75)
28-day dosing schedule: Week 16: Serotype 680.650 (0.48 to 529.75)
28-day dosing schedule: Week 16: Serotype 700.500 (0.48 to 529.75)
28-day dosing schedule: Week 16: Serotype 80.542 (0.48 to 529.75)
28-day dosing schedule: Week 16: Serotype 90.500 (0.48 to 529.75)
21-day dosing schedule: Week 18 Serotype 171.250 (1.78 to 334.37)
21-day dosing schedule: Week 18 Serotype 121.783 (0.50 to 334.37)
21-day dosing schedule: Week 18 Serotype 1470.450 (0.50 to 334.37)
21-day dosing schedule: Week 18: Serotype 1771.250 (1.78 to 337.30)
21-day dosing schedule: Week 18: Serotype 191.967 (0.53 to 334.37)
21-day dosing schedule: Week 18: Serotype 271.250 (1.78 to 337.30)
21-day dosing schedule: Week 18: Serotype 202.050 (1.78 to 457.00)
21-day dosing schedule: Week 18: Serotype 2271.250 (1.78 to 337.30)
21-day dosing schedule: Week 18: Serotype 232.050 (0.50 to 334.37)
21-day dosing schedule: Week 18: Serotype 2671.250 (1.78 to 334.37)
21-day dosing schedule: Week 18: Serotype 371.250 (2.05 to 457.00)
21-day dosing schedule: Week 18: Serotype 341.967 (0.53 to 334.37)
21-day dosing schedule: Week 18: Serotype 41.783 (0.50 to 334.37)
21-day dosing schedule: Week 18: Serotype 431.967 (0.53 to 457.00)
21-day dosing schedule: Week 18: Serotype 571.250 (1.78 to 337.30)
21-day dosing schedule: Week 18: Serotype 5171.250 (0.53 to 334.37)
21-day dosing schedule: Week 18: Serotype 5471.250 (1.78 to 334.37)
21-day dosing schedule: Week 18: Serotype 5671.250 (1.78 to 334.37)
21-day dosing schedule: Week 18: Serotype 5770.850 (0.53 to 334.37)
21-day dosing schedule: Week 18: Serotype 6824.700 (0.50 to 334.37)
21-day dosing schedule: Week 18: Serotype 701.967 (0.48 to 71.25)
21-day dosing schedule: Week 18: Serotype 82.050 (1.78 to 334.37)
21-day dosing schedule: Week 18: Serotype 970.450 (0.53 to 334.37)
SecondaryElimination Rate Constant (Kel) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)

Kel was the elimination rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase. The Kel for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20 serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · 1/hour
Elimination Rate Constant (Kel) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)
1/hourKedrion IVIG 10%
28-day dosing schedule: Week 16: Serotype 10.0016 ± 0.00081
28-day dosing schedule: Week 16: Serotype 120.0017 ± 0.00037
28-day dosing schedule: Week 16: Serotype 140.0011 ± 0.00037
28-day dosing schedule: Week 16: Serotype 170.0014 ± 0.00069
28-day dosing schedule: Week 16: Serotype 190.0010 ± 0.00039
28-day dosing schedule: Week 16: Serotype 20.0010 ± 0.00054
28-day dosing schedule: Week 16: Serotype 200.0009 ± 0.00063
28-day dosing schedule: Week 16: Serotype 220.0015 ± 0.00082
28-day dosing schedule: Week 16: Serotype 230.0010 ± 0.00038
28-day dosing schedule: Week 16: Serotype 260.0013 ± 0.00057
28-day dosing schedule: Week 16: Serotype 30.0014 ± 0.00078
28-day dosing schedule: Week 16: Serotype 340.0013 ± 0.00068
28-day dosing schedule: Week 16: Serotype 40.0013 ± 0.00011
28-day dosing schedule: Week 16: Serotype 430.0013 ± 0.00041
28-day dosing schedule: Week 16: Serotype 50.0012 ± 0.00036
28-day dosing schedule: Week 16: Serotype 510.0012 ± 0.00072
28-day dosing schedule: Week 16: Serotype 540.0009 ± 0.00052
28-day dosing schedule: Week 16: Serotype 560.0014 ± 0.00053
28-day dosing schedule: Week 16: Serotype 570.0010 ± 0.00059
28-day dosing schedule: Week 16: Serotype 680.0012 ± 0.00051
28-day dosing schedule: Week 16: Serotype 700.0011 ± 0.00047
28-day dosing schedule: Week 16: Serotype 80.0013 ± 0.00043
28-day dosing schedule: Week 16: Serotype 90.0015 ± 0.00083
21-day dosing schedule: Week 18: Serotype 10.0009
21-day dosing schedule: Week 18: Serotype 120.0014 ± 0.00030
21-day dosing schedule: Week 18: Serotype 140.0005
21-day dosing schedule: Week 18: Serotype 170.0006 ± 0.00022
21-day dosing schedule: Week 18: Serotype 190.0018 ± 0.00183
21-day dosing schedule: Week 18: Serotype 20.0008
21-day dosing schedule: Week 18: Serotype 200.0009
21-day dosing schedule: Week 18: Serotype 220.0007 ± 0.00008
21-day dosing schedule: Week 18: Serotype 230.0009 ± 0.00017
21-day dosing schedule: Week 18: Serotype 260.0008
21-day dosing schedule: Week 18: Serotype 30.0024
21-day dosing schedule: Week 18: Serotype 340.0009 ± 0.00010
21-day dosing schedule: Week 18: Serotype 40.0016 ± 0.00094
21-day dosing schedule: Week 18: Serotype 430.0026 ± 0.00104
21-day dosing schedule: Week 18: Serotype 50.0008
21-day dosing schedule: Week 18: Serotype 510.0009
21-day dosing schedule: Week 18: Serotype 540.0009
21-day dosing schedule: Week 18: Serotype 560.0007
21-day dosing schedule: Week 18: Serotype 680.0027
21-day dosing schedule: Week 18: Serotype 700.0007 ± 0.00051
21-day dosing schedule: Week 18: Serotype 80.0011
21-day dosing schedule: Week 18: Serotype 90.0008
SecondaryAverage Concentration of Anti-pneumococcal Capsular Polysaccharide the Dosing Interval (Cavg) (Overall SP Serotypes)

Average concentration of anti-pneumococcal capsular polysaccharide over the dosing interval (Cavg) was reported. The Cavg for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · mg/L
Average Concentration of Anti-pneumococcal Capsular Polysaccharide the Dosing Interval (Cavg) (Overall SP Serotypes)
mg/LKedrion IVIG 10%
28-day dosing schedule: Week 16: Serotype 11.9274 ± 1.91218
28-day dosing schedule: Week 16: Serotype 120.7389 ± 0.97027
28-day dosing schedule: Week 16: Serotype 1411.8127 ± 26.793
28-day dosing schedule: Week 16: Serotype 171.7723 ± 0.86237
28-day dosing schedule: Week 16: Serotype 193.2992 ± 1.55795
28-day dosing schedule: Week 16: Serotype 22.2719 ± 0.84758
28-day dosing schedule: Week 16: Serotype 202.6925 ± 2.27169
28-day dosing schedule: Week 16: Serotype 221.1703 ± 1.14923
28-day dosing schedule: Week 16: Serotype 231.8608 ± 2.37096
28-day dosing schedule: Week 16: Serotype 261.4473 ± 1.09160
28-day dosing schedule: Week 16: Serotype 31.4018 ± 0.57076
28-day dosing schedule: Week 16: Serotype 341.4310 ± 0.67369
28-day dosing schedule: Week 16: Serotype 40.3715 ± 0.13038
28-day dosing schedule: Week 16: Serotype 431.3909 ± 0.75449
28-day dosing schedule: Week 16: Serotype 52.2704 ± 0.91895
28-day dosing schedule: Week 16: Serotype 511.9760 ± 0.45341
28-day dosing schedule: Week 16: Serotype 542.4786 ± 0.70417
28-day dosing schedule: Week 16: Serotype 563.6552 ± 8.34613
28-day dosing schedule: Week 16: Serotype 577.7851 ± 14.9518
28-day dosing schedule: Week 16: Serotype 681.0037 ± 0.43741
28-day dosing schedule: Week 16: Serotype 701.8656 ± 1.16519
28-day dosing schedule: Week 16: Serotype 81.6553 ± 0.54282
28-day dosing schedule: Week 16: Serotype 90.8174 ± 0.30539
21-day dosing schedule: Week 18: Serotype 16.8000 ± 8.72068
21-day dosing schedule: Week 18: Serotype 120.6759 ± 0.07969
21-day dosing schedule: Week 18: Serotype 148.3407 ± 4.11626
21-day dosing schedule: Week 18: Serotype 173.3332 ± 2.49783
21-day dosing schedule: Week 18: Serotype 194.1177 ± 1.24514
21-day dosing schedule: Week 18: Serotype 23.1566 ± 1.78858
21-day dosing schedule: Week 18: Serotype 204.0521 ± 2.44372
21-day dosing schedule: Week 18: Serotype 221.3653 ± 0.45325
21-day dosing schedule: Week 18: Serotype 231.6720 ± 0.80975
21-day dosing schedule: Week 18: Serotype 262.5183 ± 2.29821
21-day dosing schedule: Week 18: Serotype 39.6039 ± 13.55999
21-day dosing schedule: Week 18: Serotype 341.4352 ± 0.21030
21-day dosing schedule: Week 18: Serotype 40.7559 ± 0.61634
21-day dosing schedule: Week 18: Serotype 431.9271 ± 0.61773
21-day dosing schedule: Week 18: Serotype 53.0491 ± 0.47615
21-day dosing schedule: Week 18: Serotype 5111.8744 ± 15.99966
21-day dosing schedule: Week 18: Serotype 548.7747 ± 10.40792
21-day dosing schedule: Week 18: Serotype 5613.4544 ± 19.77749
21-day dosing schedule: Week 18: Serotype 573.7348 ± 0.38721
21-day dosing schedule: Week 18: Serotype 681.8682 ± 1.69358
21-day dosing schedule: Week 18: Serotype 702.0323 ± 0.31507
21-day dosing schedule: Week 18: Serotype 84.2572 ± 3.86929
21-day dosing schedule: Week 18: Serotype 91.5159 ± 0.65747
SecondaryPercentage Peak Trough Fluctuation of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)

The peak trough fluctuation within complete dosing interval at steady state of anti-pneumococcal capsular polysaccharide was reported. The peak trough fluctuation for serotype 1, serotype 12, serotype 14, serotype 17, serotype 19, serotype 2, serotype 20, serotype 22, serotype 23, serotype 26, serotype 3, serotype 4, serotype 34, serotype 43, serotype 5, serotype 51, serotype 54, serotype 56, serotype 57, serotype 68, serotype 70, serotype 8 and serotype 9 was reported at Week 16 during 28-day dosing schedule and at Week 18 during 21-day dosing schedule.

Time frame:
At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion
Reported as:
Mean · percent fluctuation
Percentage Peak Trough Fluctuation of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)
percent fluctuationKedrion IVIG 10%
28-day dosing schedule: Week 16: Serotype 1128.3177 ± 62.60668
28-day dosing schedule: Week 16: Serotype 12125.2166 ± 64.54247
28-day dosing schedule: Week 16: Serotype 14107.5731 ± 40.60933
28-day dosing schedule: Week 16: Serotype 17103.6118 ± 35.89546
28-day dosing schedule: Week 16: Serotype 19110.9054 ± 50.44522
28-day dosing schedule: Week 16: Serotype 2105.2306 ± 55.00248
28-day dosing schedule: Week 16: Serotype 20114.6004 ± 41.03380
28-day dosing schedule: Week 16: Serotype 22128.1639 ± 58.30342
28-day dosing schedule: Week 16: Serotype 23116.7754 ± 45.77432
28-day dosing schedule: Week 16: Serotype 26122.7546 ± 65.89653
28-day dosing schedule: Week 16: Serotype 3139.1737 ± 50.45738
28-day dosing schedule: Week 16: Serotype 34112.0465 ± 48.26345
28-day dosing schedule: Week 16: Serotype 4117.2909 ± 65.62829
28-day dosing schedule: Week 16: Serotype 43125.0358 ± 49.91946
28-day dosing schedule: Week 16: Serotype 5124.7428 ± 49.15063
28-day dosing schedule: Week 16: Serotype 51110.9231 ± 48.65621
28-day dosing schedule: Week 16: Serotype 54123.3022 ± 53.42626
28-day dosing schedule: Week 16: Serotype 56116.6480 ± 52.81535
28-day dosing schedule: Week 16: Serotype 57111.5242 ± 42.65179
28-day dosing schedule: Week 16: Serotype 68114.0701 ± 58.01418
28-day dosing schedule: Week 16: Serotype 70109.4081 ± 43.80010
28-day dosing schedule: Week 16: Serotype 8117.3221 ± 38.97972
28-day dosing schedule: Week 16: Serotype 9130.6095 ± 65.79680
21-day dosing schedule: Week 18: Serotype 181.4603 ± 40.27141
21-day dosing schedule: Week 18: Serotype 12102.9813 ± 10.00904
21-day dosing schedule: Week 18: Serotype 1473.9639 ± 29.28795
21-day dosing schedule: Week 18: Serotype 1776.0492 ± 42.17688
21-day dosing schedule: Week 18: Serotype 1994.4390 ± 30.99072
21-day dosing schedule: Week 18: Serotype 280.1377 ± 36.22955
21-day dosing schedule: Week 18: Serotype 2083.5202 ± 42.23144
21-day dosing schedule: Week 18: Serotype 2291.9216 ± 20.16314
21-day dosing schedule: Week 18: Serotype 2384.5653 ± 31.15550
21-day dosing schedule: Week 18: Serotype 2688.7836 ± 30.46916
21-day dosing schedule: Week 18: Serotype 390.4017 ± 39.81294
21-day dosing schedule: Week 18: Serotype 3491.6269 ± 16.96157
21-day dosing schedule: Week 18: Serotype 479.5022 ± 41.16158
21-day dosing schedule: Week 18: Serotype 4381.6962 ± 28.91186
21-day dosing schedule: Week 18: Serotype 588.6356 ± 17.56577
21-day dosing schedule: Week 18: Serotype 5171.0749 ± 31.74626
21-day dosing schedule: Week 18: Serotype 5472.7200 ± 31.26330
21-day dosing schedule: Week 18: Serotype 5682.4508 ± 27.11113
21-day dosing schedule: Week 18: Serotype 5798.1611 ± 9.69314
21-day dosing schedule: Week 18: Serotype 6882.9015 ± 37.95746
21-day dosing schedule: Week 18: Serotype 7091.3286 ± 19.12896
21-day dosing schedule: Week 18: Serotype 865.5637 ± 36.02827
21-day dosing schedule: Week 18: Serotype 975.8333 ± 30.77330

Adverse events

Collected over Up to study termination visit (Week 52). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Kedrion IVIG 10%0/47 (0%)4/47 (8.5%)38/47 (80.9%)
Most frequent serious events
Most frequent serious events
EventKedrion IVIG 10%
Cholecystitis acuteHepatobiliary disorders1/47
HyperglycaemiaMetabolism and nutrition disorders1/47
OsteoarthritisMusculoskeletal and connective tissue disorders1/47
DepressionPsychiatric disorders1/47
HypotensionVascular disorders1/47
Most frequent other events
Showing 10 of 25
Most frequent other events
EventKedrion IVIG 10%
HeadacheNervous system disorders19/47
FatigueGeneral disorders12/47
NauseaGastrointestinal disorders11/47
SinusitisNervous system disorders11/47
upper respiratory tract infectionInfections and infestations8/47
Oropharyngeal painRespiratory, thoracic and mediastinal disorders8/47
DiarrhoeaGastrointestinal disorders7/47
PyrexiaGeneral disorders6/47
Coombs direct test positiveInvestigations6/47
DepressionPsychiatric disorders6/47

Baseline characteristics

The Full Analysis Set (FAS) included all participants who had received at least 1 dose of study medication.

Age, Continuous
Age, Continuous(years)Kedrion IVIG 10%
Mean52.6 ± 12.90
Sex: Female, Male
Sex: Female, Male(Participants)Kedrion IVIG 10%
Female30
Male17
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Kedrion IVIG 10%
Hispanic or Latino2
Not Hispanic or Latino44
Unknown or Not Reported1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Kedrion IVIG 10%
White45
Mexican1
White and African American1
08

Study locations

11 sites
  • Allergy Associates of the Palm Beaches
    North Palm Beach, Florida 33408, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Dr. Henry J. Kanarek - Allergy, Asthma & Immunology
    Overland Park, Kansas 66211, United States
  • Midwest Immunology Clinic and Infusion Center
    Plymouth, Minnesota 55446, United States
  • Allergy and Immunology Associates
    Little Silver, New Jersey 07739, United States
  • University of Buffalo
    Buffalo, New York 14203, United States
  • Optimed Research
    Columbus, Ohio 43235, United States
  • Ohio Clinical Research Associates, Inc.
    Mayfield Heights, Ohio 44124, United States
  • Toledo Institute of Clinical Research Inc
    Toledo, Ohio 43617, United States
  • Allergy Partners of North Texas Research
    Dallas, Texas 75230, United States
  • AARA Research Center
    Dallas, Texas 75231, United States
09

References and documents

Publications

  • Roifman CM, McNeil D, Lumry W, Wasserman RL, Kanarek H, Moy J, Zecca T, Rehman SM, Raasch J, Lehman H, Norton M, Calcinai M, Kleyn A, Perez E; CARES10 Investigator Working Group. Clinical Evaluation of Pharmacokinetics, Efficacy, and Safety of a 10% Immunoglobulin in Primary Immunodeficiency Disease (CARES10 Study). Adv Ther. 2026 Jul;43(7):3148-3164. doi: 10.1007/s12325-026-03594-4. Epub 2026 May 9. PubMed 42105146 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Dec 2020, 19 months.

Results were first posted in Jan 2022, 1 year 1 month after primary completion.

Of 25 phase 3 interventional studies under Primary Immunodeficiency Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 41. This study's 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2019
First posted
May 23, 2019
StartActual
Apr 30, 2019
Primary completionActual
Dec 21, 2020
CompletionActual
Dec 21, 2020
Results first posted
Jan 27, 2022
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03961009
Lead sponsor
Kedrion S.p.A.
Responsible party
Sponsor
First posted
May 23, 2019
Start date
Apr 30, 2019
Primary completion
Dec 21, 2020
Completion
Dec 21, 2020
Results posted
Jan 27, 2022
Last update
May 5, 2026

Study contacts

Medical Director
principal investigator · Kedrion SpA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion